WO2018075827A1 - Trinucleotide mrna cap analogs - Google Patents

Trinucleotide mrna cap analogs Download PDF

Info

Publication number
WO2018075827A1
WO2018075827A1 PCT/US2017/057481 US2017057481W WO2018075827A1 WO 2018075827 A1 WO2018075827 A1 WO 2018075827A1 US 2017057481 W US2017057481 W US 2017057481W WO 2018075827 A1 WO2018075827 A1 WO 2018075827A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ribose
ribonucleotide
methyl
guanosine
Prior art date
Application number
PCT/US2017/057481
Other languages
French (fr)
Inventor
Padmanabh Chivukula
Steven P. Tanis
Joseph E. Payne
Original Assignee
Arcturus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Therapeutics, Inc. filed Critical Arcturus Therapeutics, Inc.
Priority to EP17804982.1A priority Critical patent/EP3529255A1/en
Publication of WO2018075827A1 publication Critical patent/WO2018075827A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Definitions

  • Eukaryotic mRNAs have a cap structure at their 5'-termini.
  • the cap consists of 7-methyl guanosine (m 7 G) and a triphosphate bridge, ppp (p 3 ), linking the 5 ⁇ of m 7 G to the 5 ⁇ of the 5'-terminal nucleotide, N, denoted m 7 G(5')pppN (m 7 G(5')p 3 N).
  • the cap structure participates in assembly of the translation initiation complex by binding eukaryotic translation initiation factor 4E (eIF-4E).
  • m 7 G(5')p 3 can be used to initiate transcription with T7 or SP6 DNA-dependent RNA polymerase in vitro, it has the disadvantage of having to compete with guanine nucleotide (G) as the initiating nucleophile for transcriptional elongation. As a result of this competition, less than half of mRNA produced in vitro have a cap structure at their 5' termini.
  • G guanine nucleotide
  • cap analogues that replace the 3'-OH group with hydrogen or -OCH 3 (US 7,074,596; Kore, 2006, Nucleotides, Nucleotides, and Nucleic Acids, 25: 307-14, and Kore, 2006, Nucleotides,
  • Trinucleotide cap analogs were disclosed by Ishikawa, 2009, Nucleic Acid Symp. Ser., 53 : 129-30. These are
  • Ishikawa discloses that translational efficiency in a rabbit reticulocyte lysate system is greatest with mRNA transcribed with an animal-type, followed by a mammalian-type, the unnatural, and the plant-type cap structures, respectively, and that G(5')p 3 Ampm 7 G-RNA, a result of transcribing in a reverse orientation, was not obtained. Id.
  • a trinucleotide cap analog consisting of m 7 G(5')p 3 - NipN 2 , in which a m 7 G ribonucleotide is linked at its 5'-OH to a triphosphate bridge (p 3 ), wherein the triphosphate bridge is linked to a 5'-OH of ribonucleotide Ni, wherein Ni is linked via its 3'-OH to a phosphate, wherein the phosphate is linked to a 5'-OH of a second
  • ribonucleotide N 2 and wherein Ni or N 2 or both consist of a modified base or a modified ribose.
  • the trinucleotide cap analogs described herein provide improved transcriptional efficiency for in vitro synthesis of capped mRNA, m 7 G(5')p 3 -RNA.
  • One aspect of the description is a compound of formula m 7 G(5')p 3 (5')NipN 2 , wherein m 7 G is a ribonucleotide consisting of N 7 -methylguanine and a ribose; wherein
  • (5') ⁇ 3(5') is a 5' to 5' triphosphate linkage
  • Ni and N2 are ribonucleotides, wherein one or both of Ni and N2 consist of a base selected from N 6 -methyladenine, N ⁇ methyladenine, pseudouruacil, N 1 - methylpseudouracil, 5-iodouracil, 4-thiouracil, 2-thiouracil, 5-methyluracil, pseudoisocytosine, 5-methoxycytosine, 2-thiocytosine, 5-hydroxycytosine, N 4 - methylcytosine, 5-hydroxymethylcytosine, hypoxanthine, N ⁇ methylguanine, O 6 - methylguanine, 1-methyl-guanosine, N 2 -methyl-guanosine (m 2 G), N 2 ,N 2 -dimethyl- guanosine (m 2 ' 2 G), 2-methyl-2'-0- methyl-guanosine (m 2 Gm), N 2 ,N 2 -dimethyl-2'-0- methyl-guanosine (m 2
  • m 7 G ribonucleotide is linked at its 5'-OH to the triphosphate bridge, wherein the triphosphate bridge is linked to a 5'-OH of the Ni ribonucleotide, wherein Ni nucleotide is linked via its 3'-OH to a phosphate, p, wherein the phosphate is linked to a 5'-OH of the N2 ribonucleotide;
  • Ni is a ribonucleotide consisting of adenine, uridine, guanine, or cytidine, preferably adenine.
  • N2 consists of N 1 - methylguanine, 0 6 -methylguanine, 1-methyl-guanosine, m 2 G, m 2,2 G, m 2 Gm, m 2,2 Gm, 1-methyl- 2'-0-methyl-guanosine, m 2,7 Gm, or isoguanineadenine.
  • N2 consists of N 1 - methylguanine, 0 6 -methylguanine, or isoguanineadenine
  • Ni consists of a LNA, a UNA, or a ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent.
  • N2 is a ribonucleotide consisting of adenine, uridine, guanine, or cytidine, preferably guanine.
  • N2 is a ribonucleotide consisting of a LNA, a UNA, or a ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent.
  • m 7 G(5')p3(5')NipN2 consists of m 7 G(5')p3AmpGm, wherein Am is 2'OMe-adenine and Gm is 2'OMe-guanine.
  • m 7 G(5')p3(5')NipN2 consists of m 7 G(5')p3m 6 AmpGm, wherein 6 mAm is 2'0Me-N 6 methyladenine and Gm is 2'OMe-guanine.
  • m 7 G(5')p3(5')NipN2 consists of m 7 G(5')p3m 6 AmpGLNA, wherein 6 mAm is 2'0Me-N 6 methyladenine and GLNA is guanine bicyclic (LNA)-ribose.
  • Another embodiment is wherein at least one ribose of the m 7 G, Ni, or N2 ribonucleotide is a LNA.
  • m 7 G(5')p3(5')NipN2 consists of m 7 G(5')p3m 6 AmpGuNA, wherein 6 mAm is 2'0Me-N 6 methyladenine and GUNA is guanine seco(UNA)ribose.
  • 6 mAm is 2'0Me-N 6 methyladenine
  • GUNA is guanine seco(UNA)ribose.
  • at least one ribose of m 7 G, Ni, or N2 ribonucleotide is a UNA.
  • m 7 G(5')p3(5')NipN2 is, wherein at least one ribose of m 7 G, Ni, or N2 ribonucleotide is substituted by a 2'-Cl-C6-alkoxy, preferably 2'-OMe.
  • m 7 G(5')p3(5')NipN2 is wherein the triphosphate bridge consisting of 1, 2, or 3 phosphorothioate groups.
  • m 7 G(5')p3(5')NipN2 is wherein the compound increases the yield of 5'-capped transcripts produced by in vitro transcription compared to ACRA, for example, transcription is mediated by T7 RNA polymerase or T6 RNA polymerase.
  • m 7 G is a ribonucleotide consisting of N 7 -methylguanine and a ribose, wherein ppp is a 5' to 5' triphosphate linkage; wherein Ni and N2 are ribonucleotides, wherein one or both of Ni and N2 ribonucleotides consist of a base selected from adenine, uracil, cytosine, or guanine; and a bicyclic (LNA) ribose, a seco (UNA) ribose, or a modified ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent; and
  • m 7 G ribonucleotide is linked at its 5'-OH to the triphosphate bridge, wherein the triphosphate bridge is linked to a 5'-OH of the Ni ribonucleotide, wherein Ni nucleotide is linked via its 3'-OH to a phosphate, p, wherein the phosphate is linked to a 5'-OH of the N2 ribonucleotide; or a salt or solvated form thereof.
  • the m 7 G ribonucleotide of the trinucleotide cap analog is modified so that the base is substituted with hypoxanthine, rr ⁇ G, m 6 G, or isoguanine.
  • one or both of the 2'-OH or the 3 ⁇ groups of the ribose group of the m 7 G ribonucleotide are substituted by fluoro or C1-C6 alkoxy group, or the ribose is substituted by bicyclic (LNA) or seco (UNA) ribose.
  • the Ni and N2 ribonucleotides each consists of a base independently selected from adenine, uracil, cytosine, guanine, or an analog thereof, and a sugar selected from ribose, modified ribose, bicyclic ribose, or seco ribose.
  • Another aspect of the description is a method of synthesizing mRNA in vitro from DNA by using the trinucleotide cap analog according to description herein to initiate transcription.
  • the in vitro transcription uses a DNA-dependent RNA polymerase, e.g., commercially available bacteriophage T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase.
  • Another aspect of the description is mRNA produced by in vitro transcription using the trinucleotide cap analog described herein.
  • a preferred embodiment is an mRNA produced the description herein that initiates translation of a protein.
  • Another preferred embodiment is an mRNA produced by the methods herein that suppresses translation of a protein.
  • Another embodiment is a pharmaceutical composition comprising the mRNA described herein and pharmaceutical excipients.
  • the pharmaceutical composition comprises the mRNA encapsulated in a liposomal nanoparticle.
  • Another aspect of the description is a method of treating a disease, comprising administering the pharmaceutical composition described herein to a subject in need thereof.
  • kits comprising the trinucleotide cap analog described herein.
  • the kit comprises a T7 RNA polymerase, a T3 RNA polymerase, or a SP6 RNA polymerase.
  • FIG. 1 shows synthesis of m 7 GDP-IM (3) from GDP (1) by step i to
  • FIG. 2 shows synthesis of 5'-0-DMT-2'0-Me-N 6 benzoyl-AMP-PhC (6) from 2'OMe-adenosine (4) to first form a TMS-modified, benzoyl-m 6 -2'-OMe-adenosine which is benzoylated, then desilylated, and further protected as a DMTr ether (5) at step i.
  • the introduction of the phosphate moiety (step ii) then gives 6.
  • FIG. 3 shows synthesis of 2'-0-Me,3'-0-isobutyryl,N 2 -isobutyrylguanosine (9) from 2'OMe-guanosine (7) to produce intermediate N 2 -isobuyryl-2'-0-methylguanosine (8) in step i, in which the 5'-OH is protected as a DMTr ether, then the 3'-OH is isobutyrylated and finally the DMTr group is removed in step ii to give 9.
  • FIG. 4 shows synthesis of protected 2'-OMeAp-2'-OMeG dinucleotide (10) in step i by reaction of 3'-p-2'-OMeA (6) with 2'OMe guanosine (9).
  • FIG. 5 shows removal of the protective groups of 2'0MeAp2'0MeG
  • dinucleotide (10) in two steps: (i) to produce a 2'-OMeA-2'-OMeG dinucleotide compound 11 and phosphate introduction (ii) to produce 2'0MeAp2'0MeG dinucleotide 5 '-monophosphate (12).
  • FIG. 6 shows synthesis of m 7 G(5')ppp2'OMeAp2'OMeG (13) by reaction (i) of the ammonium salt of pApG (12) with the sodium salt of m 7 GDP-IM (3).
  • FIG. 7 shows synthesis of m 6 -benzoyl-2'-OMe-AMP-PhCl (18) from 2'OMe- adenosine (14) by first producing intermediate 15 (i), converting to intermediate 16 (ii), forming TMS-modified, mono-benzoylated m 6 2'OMe-adenosine which is desilylated to give (17) (iii), and protection of the 5'-OH as a DMTr ether followed by phosphate introduction (iv) gives 18.
  • FIG. 8 shows formation of dinucleotide m 6 2'OMeAp2'OMeG (21) by combining benzoyl-3'-p- m 6 2'-OMeA (18) with protected 2'OMe adenosine (9) to produce intermediate m 6 2'OMeAp2'OMeG dinucleotide (19) in step i.
  • the protective groups of m 6 2'OMeAp2'OMeG dinucleotide intermediate compound are removed (ii) to produce m 6 2'OMeA-2'OMeG dinucleotide (20), which is phosphorylated (iii) to give 21.
  • FIG. 9 shows production of trinucleotide cap analog, m 7 G(5')ppp
  • FIG. 10 shows multistep synthesis of 2'-0,4'-C-methylene-linked bicyclic guanine nucleotide (32) from (3aS,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3- d][l,3]dioxole-5,5-diyl)dimethanol (23).
  • This intermediate is fused (iii) with butyrated guanine to produce a guanine nucleotide (26) as a precursor (iv) to production of bicycle guanine nucleotide 27.
  • the 5'OMs of bicyclic guanine 27 benzoylated (v) to produce benzoate-intermediate 28, and is then hydrolyzed (vi) to produce compound 29 having a free 5 ⁇ .
  • Intermediate 29 is further deprotected (vii) to obtain compound 30 with free 3' and 5' OH groups.
  • the 5' OH group of compound 30 is blocked by DMTrCl (viii) to produce compound 31, which is acylated (viii) to produce the locked guanyl nucleotide (32).
  • FIG. 11 shows synthesis of nucleotide m 6 2'OMeAp-locked-2'OMeG (35) by (i) combining locked guanyl nucleotide (32) with benzoylated 3'-p-m 6 2'-OMeA (18) to produce intermediate dinucleotide (33).
  • the dinucleotide is deprotected (ii) to produce m 6 2'OMeA- locked-2'-OMeG dinucleotide (34), which is phosphorylated (iii) to give 35.
  • FIG. 12 shows synthesis of trinucleotide cap analog, m 7 G(5')pppm 6 2'OMeAp-locked-2'-OMeG (36) by combining the ammonium salt of m 6 2'-OMeAp-locked-2'-OMeG dinucleotide 5'-monophosphate (35) with the sodium salt of m 7 GDP-IM (3)
  • FIG. 13 shows synthesis of 2'OMe-seco-3'-0-isobutyryl,N 2 -isobutyrylguanosine (43).
  • the 5' OH group of N sobutyrylguanosine (37) is blocked with DMTrCl to produce intermediate 38 (i), which is converted (ii) to an "unlocked” form, 2'-0-benzoylated secoguanine (39).
  • the 3'-OH group of the 2'-0-benzoylated secoguanine is protected by TBDMSC1 (40).
  • the 2'-0-benzoyl group of intermediate 40 is removed (iv) to yield the free 2'-OH group (41), which is methylated (v) to yield intermediated 42.
  • the silyl group is removed from the 3'-OH of intermediate 42 and the 3-OH group is butyrylated (v) to produce secoguanine (43) after deblocking of the 5'-ODMTr ether.
  • FIG. 14 shows synthesis of p-2'-OMe-m 6 Ap-seco-2'-OMeG (46).
  • Protected 2'0MeAp2'0MeG dinucleotide (44) is produced by combining 3'-p-2'-OMeA (18) with protected 2'-OMe secoguanosine (43) to produce intermediate 44 (i).
  • intermediate 44 are removed (ii) to produce a 2'-OMeA-2'-OMeG dinucleotide (45).
  • the 5'- hydroxy group of the adenosine group is phosphorylated (iii) to produce 2'-OMe-m 6 Ap-seco-2'- OMeG 5'-monophosphate (46).
  • FIG. 15 shows synthesis of trinucleotide cap analog, m 7 G(5')pppm 6 2'-OMeAp- seco-2'-OMeG (47) from ammonium salt of 2'-OMe-m 6 Ap-seco-2'-OMeG 5 '-monophosphate (46) and the sodium salt of m 7 GDP-IM (3).
  • FIG. 15 shows synthesis of trinucleotide cap analog, m 7 G(5')pppm 6 2'-OMeAp- seco-2'-OMeG (47) from ammonium salt of 2'-OMe-m 6 Ap-seco-2'-OMeG 5 '-monophosphate (46) and the sodium salt of m 7 GDP-IM (3).
  • 16 shows expression of m 7 G(5')ppp-RNA transcribed from ARC CAP1 (m 7 G(5')p3AmpG); ARCA (3'-OMe-m 7 G(5')p3G); or VACCINIA, without ARC CAP1 or ARC A, by post-transcriptional capping by a vaccinia capping enzyme.
  • Me means "CH 3 "
  • OCft or "OMe” denotes an oxygen atom bound to a methyl group
  • Et denotes "C2H5".
  • Cap herein means a non-extendible trinucleotide that facilitates translation or localization, and/or prevents degradation of an RNA transcript when incorporated at the 5' end of an RNA transcript. It consists in nature of the modified base 7-methylguanosine joined in the opposite orientation, 5' to 5' rather than 5' to 3', to the rest of the RNA molecule via three phosphate groups i.e., PI-guanosine-5'-yl P3-7-methylguanosine-5'-yl triphosphate
  • Hydrate is a solvate wherein the solvent molecule is H2O.
  • a "cap analog” means a structural derivative of an RNA cap that may differ by as little as a single element. Cap analog is used for the synthesis of 5' capped RNA molecules in in vitro transcription reactions. Substitution of cap analog for a portion of the GTP in a transcription reaction results in the incorporation of the cap structure into a corresponding fraction of the transcripts. Capped mRNAs are generally translated more efficiently in reticulocyte lysate and wheat germ in vitro translation systems. In vitro transcripts must be capped for microinjection experiments because uncapped mRNAs are rapidly degraded. Cap analogs can also be used as a highly specific inhibitor of the initiation step of protein synthesis.
  • Enzymatically incorporatable means a nucleotide is capable of being enzymatically incorporated onto the terminus, e.g. 3' terminus, of a polynucleotide chain, or internally through nick-translation of a polynucleotide chain, through action of a template- dependent or template-independent polymerase enzyme.
  • a nucleotide-5 '-triphosphate is an example of an enzymatically incorporatable nucleotide.
  • Enzymatically extendable or "3' extendable” means a nucleotide or polynuceotide that is capable of being appended to a nucleotide or polynucleotide by enzyme action.
  • a polynucleotide containing a 3' hydroxyl group is an example of an enzymatically extendable polynucleotide.
  • a "locked nucleic acid” means a ribonucleotide in which there is a bridge between the 2 ⁇ and 4'C methylene bicyclonucleotide monomers.
  • nucleobase means a nitrogen containing heterocyclic moiety nucleobase.
  • suitable nucleobases include: adenine, cytosine, guanine, thymine, uracil, or analogs thereof, e.g., 5-propynyl-uracil, 2-thio-5-propynyl-uracil, 5-methylcytosine, pseudoisocytosine, 2-thiouracil, 2-thiothymine, 2-aminopurine, N9-(2-amino-6-chloropurine), N9-(2,6-diaminopurine), hypoxanthine, N9-(7-deaza-guanine), N9-(7-deaza-8-aza-guanine) and N8-(8-aza-7-deazaadenine).
  • a "ribonucleotide” or “nucleotide” herein means a compound consisting of a nucleobase linked to the C- carbon of a ribose sugar or analog thereof.
  • the ribose or analog may be substituted or unsubstituted.
  • Substituted ribose sugars include, but are not limited to, those riboses in which one or more of the carbon atoms, preferably the 3 '-carbon atom, is substituted with one or more of the same or different substituents such as— R,— OR,— NRR or halogen ⁇ e.g., fluoro, chloro, bromo, or iodo), where each R group is independently— H, Ci-C 6 alkyl or C 6 -Ci4 aryl or arylalkyl.
  • the nucleobase is A or G
  • the ribose sugar is attached to the N 9 -position of the nucleobase.
  • the pentose sugar is attached to the ⁇ -position of the nucleobase.
  • ribose analogs include arabinose, 2'-0-methyl ribose, UNA, and LNA analogs.
  • a "ribonucleotide” means a phosphate ester of a ribonucleotide as a monomer unit or within a polynucleotide.
  • nucleotide triphosphate means a nucleotide with a triphosphate ester group at the 5' position.
  • Alkyl "CI, C2, C3, C4, C5 or C6 alkyl” or “C1-C6 alkyl” is intended to include CI, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or e branched saturated aliphatic hydrocarbon groups.
  • C1-C6 alkyl is intended to include CI, C2, C3, C4, C5 and C6 alkyl groups.
  • alkyl examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl or n-hexyl.
  • a straight chain or branched alkyl has six or fewer carbon atoms (e.g. , C1-C6 for straight chain, C3-C6 for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms.
  • Ribonucleotides and/or ribonucleotides comprise ribose or a ribose analog.
  • Ring analog includes, e.g., substituted or unsubstituted furanoses having more or fewer than 5 ring atoms, e.g., erythroses and hexoses and substituted or unsubstituted 3- 6 carbon acyclic sugars (e.g., UNA).
  • Typical substituted furanoses and acyclic sugars are those in which one or more of the carbon atoms are substituted with one or more of the same or different— R,— OR,— NRR or halogen groups, where each R is independently— H, (Ci-C 6 ) alkyl or (C1-C14) aryl.
  • substituted furanoses having 5 ring atoms include but are not limited to 2'-deoxyribose, 2'-(Ci-C6)alkylribose, 2'-(Ci-C6)alkoxyribose, 2'-(Cs- Ci4)aryloxyribose, 2',3'-dideoxyribose, 2',3'-didehydroribose, 2'-deoxy-3'-haloribose, 2'-deoxy- 3'-fluororibose, 2'-deoxy-3'-chlororibose, 2'-deoxy-3'-aminoribose, 2'-deoxy-3'-(Ci- C6)alkylribose, 2'-deoxy-3'-(Ci-C6)alkoxyribose, 2'-deoxy-3'-(C5-Ci4)aryloxyribose, 3'-(Ci- C6)alkylrib
  • unlocked ribonucleic acid having the structure
  • Polynucleotide mean single stranded or double stranded polymers of nucleotide monomers, including ribonucleotides (RNA) and 2'- deoxyribonucleotides (DNA) linked by internucleotide phosphodiester bond linkages.
  • RNA ribonucleotides
  • DNA 2'- deoxyribonucleotides
  • a polynucleotide may be composed entirely of deoxyribonucleotides, entirely of ribonucleotides or chimeric mixtures thereof.
  • Substituted means substitution with specified groups other than hydrogen, or with one or more groups, moieties or radicals which can be the same or different, with each, for example, being independently selected.
  • trinucleotide compounds of described herein form salts that are also within the scope of this disclosure.
  • Reference to a trinucleotide compound herein is understood to include reference to salts thereof, unless otherwise indicated.
  • Salt(s) mean acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • a trinucleotide compound contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term “salt(s)" as used herein.
  • the salts can be
  • Salts of the trinucleotide compounds may be formed, for example, by reacting the trinucleotide compounds with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecyl sulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, benzenesulfonates, toluenesulfonates, nitrobenzene sulfonates, 2- napthalenesulfonates, nicotinates, n
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines,
  • dicyclohexylamines dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N- methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, trialkyl amines such as triethyl amine, and salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), allylic and propargylic halides such as l-bromo-2-propene and l-bromo-2-propyne, and others.
  • lower alkyl halides e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iod
  • Solidvate means a physical association of a trinucleotide compound of this disclosure with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. Solvate encompasses both solution- phase and isolatable solvates. Non-limiting examples of suitable solvates include water, ethanolates, methanolates, and the like. Trinucleotide compounds of the disclosure can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for the purposes of this disclosure.
  • Trinucleotide compounds of the disclosure may exist in their tautomeric form. All such tautomeric forms are contemplated herein as part of the present disclosure.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present trinucleotide compounds including those of the salts, solvates and prodrugs of the trinucleotide compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this disclosure.
  • Individual stereoisomers of the trinucleotide compounds of this disclosure may, for example, be
  • the trinucleotide compounds of the disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such trinucleotide compounds.
  • Unnatural proportions of an isotope may be defined as ranging from the amount found in nature to an amount consisting of 100% of the atom in question.
  • the trinucleotide compounds may incorporate radioactive isotopes, such as, for example, tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C), or non-radioactive isotopes, such as deuterium ( 2 H), carbon- 13 ( 13 C), or isotopes of nitrogen, oxygen and sulfur.
  • isotopic variants of the trinucleotide compounds of the invention may find additional utility, including but not limited to, as diagnostic and/or imaging reagents, or as cytotoxic/radiotoxic therapeutic agents.
  • isotopic variants of the trinucleotide compounds of the invention can have altered pharmacokinetic and pharmacodynamic characteristics which can contribute to enhanced safety, tolerability or efficacy during treatment. All isotopic variations of the trinucleotide compounds of the description herein, whether radioactive or not, are intended to be encompassed within the scope of the description herein.
  • Inhibitors and “antagonists”, or “activators” and “agonists” mean inhibitory or activating molecules, respectively, for example, for the activation of, e.g., a ligand, receptor, cofactor, gene, cell, tissue, or organ.
  • Inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell.
  • Activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up- regulate, e.g., a gene, protein, ligand, receptor, or cell.
  • An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity.
  • An "agonist” is a molecule that interacts with a target to cause or promote an increase in the activation of the target.
  • An "antagonist” is a molecule that opposes the action(s) of an agonist.
  • An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist.
  • the "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the
  • Proliferative activity means an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.
  • trinucleotide cap analogs disclosed herein are used for improving the synthesis of 5' capped RNA molecules in in vitro transcription reactions. Substitution of cap analog for a portion of the GTP in a transcription reaction results in the incorporation of the cap structure into a corresponding fraction of the transcripts.
  • RNA Transcription of RNA usually starts with a nucleotide triphosphate (usually a purine, A or G). When transcription occurs in vitro, it typically includes a phage RNA polymerase such as T7, T3 or SP6, a DNA template containing a phage polymerase promoter, nucleotides (ATP, GTP, CTP and UTP) and a buffer containing magnesium salt.
  • a phage RNA polymerase such as T7, T3 or SP6
  • a DNA template containing a phage polymerase promoter a DNA template containing a phage polymerase promoter
  • nucleotides ATP, GTP, CTP and UTP
  • the synthesis of capped RNA includes the incorporation of a cap ⁇ e.g., m 7 GpppG) or a cap analog (such as those described herein) in the transcription reaction.
  • a cap ⁇ e.g., m 7 GpppG
  • the mMESSAGE mMACHINE® SP6 Transcription Kit and SP7 Ultra Kit recommends this ratio and will typically yield 80% capped RNA to 20% uncapped RNA, although total yields of total RNA are lower as GTP concentration becomes rate limiting as GTP is necessary for the elongation of the transcript.
  • Capped mRNAs are generally translated more efficiently in reticulocyte lysine and wheat germ in vitro translation systems. It is important that in vitro transcripts be capped for microinjection experiments because uncapped mRNAs are rapidly degraded. Cap analogs are also used as a highly specific inhibitor of the initiation step of protein synthesis.
  • the 5' cap structure enhances the translation of mRNA by helping to bind the eukaryotic ribosome and assuring recognition of the proper AUG initiator codon. This function may vary with the translation system and with the specific mRNA being synthesized.
  • the consensus sequence 5'-GCCACCAUGG-3' also known as the "Kozak" sequence, is considered to be the strongest ribosomal binding signal in eukaryotic mRNA.
  • the key elements are the 5' G residue at the +1 position and the A residue at the 3' position of the mRNA.
  • the mRNA can be transfected into a cell to be translated intracellularly.
  • Cells for use in in vivo translation include any patient cell for which it is desired to express a protein of interest.
  • Cells include hematopoietic cells (e.g., T cells, dendritic cells, macrophages, etc.), bone marrow cells, tissue culture cells, germ cells, and the like.
  • compositions comprising modified capped RNA as described herein can be used for in vitro transcription, in vitro translation, and in vivo translation, for example.
  • Current biotechnology efforts for in vitro, in situ, and in vivo protein production will also benefit from these methods and compositions.
  • compositions provided herein are useful for therapeutic purposes.
  • the present technology may be useful for generating vaccines against infectious diseases or cancers.
  • Alkyne-derivatized capped RNA can be used to produce non-infectious particles of Venezuelan Equine Encephalitis virus containing an RNA encoding immunogen. These non-replicating viral particles can be injected into humans where they can enter host cells.
  • the viral particles dissociate and the mRNA encoding the immunogen is translated into protein. These proteins can induce an immune response.
  • These types of vaccines are expected to be useful for human immunodeficiency virus (HIV), feline immunodeficiency virus, human papilloma virus type 16, tumors, lassa virus, Ebola virus, Marburg virus, anthrax toxin from Bacillus anthraces, and botulinum toxin.
  • HIV human immunodeficiency virus
  • feline immunodeficiency virus human papilloma virus type 16
  • tumors lassa virus
  • Ebola virus Marburg virus
  • anthrax toxin from Bacillus anthraces and botulinum toxin.
  • botulinum toxin botulinum toxin.
  • Such oligomers or oligonucleotides may be prepared by solid state synthesis or by other means known to those skilled in the art.
  • 2'-0-alkyl guanosine 2'-0-alkyl guanosine
  • phosphoramidites and derivatives thereof may be incorporated into oligonucleotides using standard phosphoramidite chemistry. Incorporation of 2'-0-alkyl guanosine nucleotides may confer desirable characteristics to an oligonucleotide such as enhanced resistance to nuclease.
  • Oligonucleotide or "oligomer” as used herein means a polynucleotide formed from naturally occurring bases and furanosyl groups joined by native phosphodiester bonds. Oligonucleotides of the description herein will, of course, comprise at least one 2'-0-alkyl guanosine or derivative thereof. Thus, this term effectively refers to naturally occurring species or synthetic species formed from naturally occurring subunits or their close homologs. The term “oligonucleotide” or “oligomer” may also refer to moieties which have portions similar to naturally occurring oligonucleotides but which have non-naturally occurring portions.
  • oligonucleotides may have altered sugars, altered base moieties, or altered inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur-containing species which are known for use in the art. In accordance with some preferred embodiments, at least some of the phosphodiester bonds of the oligonucleotide have been substituted with a structure which functions to enhance the stability of the oligonucleotide or the ability of the oligonucleotide to penetrate into the region of cells where the messenger RNA is located.
  • substitutions comprise phosphorothioate bonds, phosphotriesters, methyl phosphonate bonds, short chain alkyl or cycloalkyl structures or short chain heteroatomic or heterocyclic structures.
  • Other preferred substitutions are CH 2 — NH— O— CH 2 , CH 2 — N(CH 3 )— O— CH 2 , CH 2 — O— N(CH 3 )— CH 2 , CH 2 — N(CH 3 )— N(CH 3 )— CH 2 and O— N(CH 3 )— CH 2 — CH 2 structures where phosphodiester intersugar linkage is replaced by the substitutions.
  • morpholino structures are also preferred.
  • the phosphodiester bonds are substituted with other structures which are, at once, substantially non-ionic and non-chiral, or with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in practice of the invention.
  • Oligonucleotides may also include species which include at least some modified base forms.
  • purines and pyrimidines other than those normally found in nature may be so employed.
  • Suitable bases include modifications on the furanosyl portion of the nucleotide subunits, in addition to 2'-0-alkyl modifications of the description herein, may also be effected, as long as the essential tenets of this invention are adhered to. Examples of such modifications are 2'-halogen-substituted nucleotides.
  • modifications at the 2' position of sugar moieties which are useful in the description herein are OH, SH, SCH 3 , F, OCN, 0(CH 2 ) n H 2 , CI, Br, CN, CF 3 , OCF 3 , S— , OC1-OC12, O-alkenyl, O-alkynal, or N-alkyl; S— or N-alkenyl; SOCH 3 , S0 2 CH 3 ; ON0 2 ; N0 2 ; N 3 ; H 2 ; heterocycloalkyl; heterocycloalkaryl;
  • oligonucleotide may also comprise other modifications consistent with the spirit of this invention. Such oligonucleotides are best described as being functionally interchangeable with yet structurally distinct from natural oligonucleotides. All such oligonucleotides are comprehended by this invention so long as they effectively function as subunits in the oligonucleotide.
  • oligonucleotides of the description herein are from about 6 to about 50 nucleotides in length. In still more preferred embodiments of the description herein oligonucleotides are from about 12 to about 20 nucleotides in length.
  • Intercalators are molecules which insert themselves between neighboring bases of an oligonucleotide, e.g., acridine.
  • Reporter molecules are molecules which may aid in the identification of a molecule, either visually or otherwise.
  • biotin and various fluorophores are effective reporter groups.
  • Conjugates, or bifunctional linkers effectively join two groups.
  • Some conjugates are commercially available such as biotin or 3' maleimidobenzoyl-N-hydroxy-succinimide.
  • Pharmacodymanic property improvement means, in this context, improved oligonucleotide uptake, enhanced oligonucleotide resistance to degradation, and/or strengthened sequence-specific hybridization with RNA. Such groups do not initiate chemical reactions.
  • Groups that enhance the pharmacodynamic properties of an oligonucleotide preferably include alkyl chains, polyamines, ethylene glycols, polyamides, alkyl chains, aminoalkyl chains and amphipathic moieties.
  • Pharmacokinetic property improvement means improved oligonucleotide uptake, distribution, metabolism or excretion.
  • Antisense therapy involves the use of oligonucleotides which are specifically hybridizable to target RNA or DNA. Oligonucleotides of the description herein are preferably specifically hydridizable with a target region. "Specifically hybridizable” means capable of forming a stable duplex with a target DNA or RNA. Upon binding to, or forming a stable duplex with, the target RNA or DNA, the antisense oligonucleotide can selectively inhibit the genetic expression of these nucleic acids or can induce some other events such as destruction of a targeted RNA or DNA or activation of gene expression.
  • Destruction of targeted RNA can be effected by RNase H activation or by linking strand cleavers to the oligonucleotide.
  • the oligonucleotide portions of trinucleotide compounds of the description herein are at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%) complementary to a target sequence.
  • the oligonucleotide portions of trinucleotide compounds of the description herein are at least 60%), 70%, or 80%> complementary to a target sequence. 100% complementarity of the oligonucleotide portions of trinucleotide compounds of the description herein to a target sequence is most preferred.
  • the description herein the
  • oligonucleotide portions may be specifically hybridizable with DNA or RNA from Candida, papilloma virus, Epstein Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, influenza virus and cytomegalovirus.
  • 2-O-alkyl guanosine containing oligonucleotides of the description herein may be used to modulate the production of protein by contacting a selected sequence of RNA or DNA coding for a selected protein with an 2'-0-alkyl guanosine containing oligonucleotide of the description herein having a sequence of nucleotide bases specifically hybridizable with said selected sequence of RNA or DNA coding for said protein.
  • the oligonucleotides of the description herein can be used in diagnostics, therapeutics and as research reagents.
  • an animal having a disease characterized by the undesired production of a protein is contacted with an oligonucleotide of the description herein having a sequence of nucleotide bases specifically hybridizable with a selected sequence of RNA or DNA coding for said protein.
  • compositions described herein involves isolating dendritic cells (DCs) from a patient and then transfecting the dendritic cells with derivatized capped RNA as described herein encoding immunogen.
  • the dendritic cells translate the derivatized capped RNA into at least one protein that induces an immune response against this protein.
  • the cap analogs provided herein can be used for providing mRNAs for antigen delivery to DCs for the purpose of immunotherapy against cancer and infectious diseases.
  • Other uses include reprogramming differentiated cells to pluripotency and/or to re-program pluripotent cells using capped RNA described herein to specifically differentiate cell types by continuous transfection of specific derivatized-capped mRNAs over a time-period necessary for changing the cell differentiation.
  • Trinucleotide compounds of the disclosure may be in the form of compositions suitable for administration to a subject.
  • compositions are "pharmaceutical compositions" comprising at least one trinucleotide compound and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients.
  • trinucleotide compounds of the disclosure are present in a therapeutically acceptable amount.
  • the pharmaceutical compositions may be used in the methods of the description herein; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.
  • compositions of the description herein can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein.
  • pharmaceutical compositions may be used in combination with other therapeutically active agents or trinucleotide compounds as described herein in order to treat or prevent the diseases, disorders and conditions as contemplated by the description herein.
  • Suitable routes of administration include oral, parenteral ⁇ e.g., intramuscular, intravenous, subcutaneous ⁇ e.g., injection or implant), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebroventricular), nasal, vaginal, sublingual, intraocular, rectal, topical ⁇ e.g., transdermal), sublingual and inhalation.
  • Trinucleotide compounds of the disclosure may be administered to a subject in an amount that is dependent upon, for example, the goal of administration ⁇ e.g., the degree of resolution desired); the age, weight, sex, and health and physical condition of the subject to which the formulation is being administered; the route of administration; and the nature of the disease, disorder, condition or symptom thereof.
  • the dosing regimen may also take into consideration the existence, nature, and extent of any adverse effects associated with the agent(s) being administered. Effective dosage amounts and dosage regimens can readily be determined from, for example, safety and dose-escalation trials, in vivo studies (e.g., animal models), and other methods known to the skilled artisan.
  • dosing parameters dictate that the dosage amount be less than an amount that could be irreversibly toxic to the subject (the maximum tolerated dose (MTD)) and not less than an amount required to produce a measurable effect on the subject.
  • MTD maximum tolerated dose
  • Such amounts are determined by, for example, the pharmacokinetic and pharmacodynamic parameters associated with ADME, taking into consideration the route of administration and other factors.
  • An effective dose is the dose or amount of an agent that produces a therapeutic response or desired effect in some fraction of the subjects taking it.
  • the "median effective dose” or ED50 of an agent is the dose or amount of an agent that produces a therapeutic response or desired effect in 50% of the population to which it is administered.
  • the ED50 is commonly used as a measure of reasonable expectance of an agent's effect, it is not necessarily the dose that a clinician might deem appropriate taking into consideration all relevant factors.
  • the effective amount is more than the calculated ED50, in other situations the effective amount is less than the calculated ED50, and in still other situations the effective amount is the same as the calculated ED50.
  • the amount and frequency of administration of the trinucleotide compounds of this disclosure and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
  • the imidazole product is precipitated from a solution of anhydrous sodium perchlorate in dry acetone and, after cooling to 4°C, the precipitate is filtered, washed in acetone, and dried overnight under vacuum to yield m 7 GDP-IM (compound 3).
  • step ii) compound 5
  • step ii compound 5
  • step ii compound 5
  • step ii) by reaction with 4-chlorophenyl dichlorophosphate as a 3'-0-phosphorylating agent (step ii) to produce 5 ⁇ - DMT-2'-0-Me-N 6 benzoyl-AMP-PhCl (compound 6).
  • step i) were removed to produce a 2'-OMeA-2'- OMeG dinucleotide compound 11.
  • the 5'-hydroxy group of the adenosine group was phosphorylated according to the method of Lewdorowicz 2007 (FIG. 5, step ii).
  • Phosphorus trichloride oxide in trimethyl phosphate was cooled to 4°C and the 5'-0-guanine-adenine dinucleotide-3'-0 compound 10 was added and stirred at 4°C for 3 hours.
  • Tetraethylammoniuum bromide (TEAB) was added to neutralize the mixture to produce the 2'0MeAp2'0MeG dinucleotide 5'-monophosphate (FIG. 5, compound 12).
  • Trinucleotide cap analog m 7 G(5 , )ppp2 , OMeAp2'OMeG (FIG , compound 20).
  • the trinucleotide cap analog is produced by the method of Lewdorowicz 2007.
  • a mixture of ammonium salt of pApG (compound 19 produced in Example 7), four equivalents of a sodium salt of m 7 GDP-IM (compound 1 produced in Example 1), and ZnC12 in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield
  • step iii The m 6 2'OMe-adenosine product (compound 16) was protected by the method of Zhu, 2003, Synthetic Communications, 33 : 1233-43 (hereby incorporated by reference) (step iii).
  • the adenosine compound was reacted with 1.1 equivalents of TMSCl per hydroxy group together with 1.2 equivalents of benzoyl chloride to produce TMS-modified, mono-benzoylated m 6 2'OMe-adenosine.
  • the TMSA groups were removed under aqueous acidic conditions in THF-TFA to give compound 17 (step iii).
  • Trinucleotide cap analog m 7 G(5')ppp m 6 2'OMeAp2'OMeG (compound 22, FIG. 9).
  • the trinucleotide cap analog is produced by the method described in Example 5.
  • a mixture of ammonium salt of pApG (compound 21 produced in Example 7), four equivalents of a sodium salt of m 7 GDP-IM (compound 3 produced in Example 1), and ZnCh in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield m 7 G(5')pppm 6 2'OMeAp2'OMeG (compound 22).
  • the diol compound 23 in anhydrous pyridine was cooled in an ice bath and methanesulfonyl chloride (MsCl) is added. The mixture is stirred for 1 hour at room temperature, diluted with ethyl ether, and washed with water. The organic layer was dried (Na2S0 4 ), concentrated under reduced pressure, co-evaporated with toluene, and dried in vacuo (FIG. 10, step i) to yield compound 24.
  • a solution of this product in 80% trifluoroacetic acid was stirred at room temperature for one hour. The solvents were removed under pressure and the residue is dissolved in dichloromethane (DCM) and washed with saturated NaHCCb to yield compound 24.
  • DCM dichloromethane
  • N,O-i3 ⁇ 4 ' s(trimethylsilyl)acetamide (BSA) was added to a mixture of compound 25 and butyrated guanine in anhydrous acetonitrile. After refluxing for one hour, trimethylsilyl triflate is added and refluxing was continued further for 4 hours to produce a guanine nucleotide compound 26 (FIG. 10, step iii). The solution was cooled to room temperature, diluted with DCM, and washed with saturated NaHCCb. The organic layer was dried, and concentrated under reduced pressure to obtain modified guanine nucleotide intermediate compound 26.
  • BSA N,O-i3 ⁇ 4 ' s(trimethylsilyl)acetamide
  • the 3'-OH group of the nucleotide 31 was blocked by an acyl group according to the method of WO 2009/124238 (hereby incorporated by reference).
  • the 3' hydroxy group compound 31 was acylated with alkoyl chloride, triethylamine in DCM, followed by removal of the 5'O-DMTr group with hexafluoroisopropanol or aqueous acid to produce the locked guanyl nucleotide, compound 32 (FIG. 10, step viii).
  • Tetraethylammoniuum bromide (TEAB) was added to neutralize the mixture to produce the m 6 2'-OMeAp-locked-2'-OMeG dinucleotide 5'-monophosphate (FIG. 11, compound 35).
  • Guanosine compound 38 was converted to an "unlocked" form of compound 39 by the method of Landkjaer, 2009, BiorgMed Chem, 17:5420-25 (hereby incorporated by reference).
  • the DMTr guanosine compound 38 was dissolved in a stirred mixture of dioxane and water. To this mixture was added NaI0 4 dissolved in water, stirred for one hour, and further dioxane is added. The suspension was filtered and the filter cake was washed with dioxane. The filtrates were combined and sodium borohydride was added and the mixture stirred for 30 minutes (FIG. 17, step ii). The mixture was neutralized by addition of pyridine:acetic acid buffer. After evaporation, DCM is added and the mixture was washed with saturated aqueous NaHC03. The organic phase was separated and evaporated to dryness under reduced pressure, to yield 5'0-DMT-2',3'-secoguanine.
  • 2'-0-benzoyl-5'-0-DMT-2',3'-secoguanine compound 39 was prepared from 5'0-DMT-2',3'-secoguanine by the method of Landkjaer 2009. The nucleotide was co- evaporated with anhydrous toluene and dried for 12 hours in vacuo. The residue was dissolved at room temperature in anhydrous mixture of DCM with pyridine and cooled to -78°C. Benzoyl chloride was added over 15 minutes with stirring for 1 hour at -78°C. The mixture was warmed to room temperature, and ethanol was added and the mixture was washed with saturated aqueous NaHC03 and the separated aqueous phase was back-extracted with DCE. The organic phases were combined and evaporated to dryness to yield the 2'-0-benzoylated secoguanine compound 39 (FIG. 13, step ii).
  • the 2'-0-benzoyl group compound 40 was removed by the method of Nishino, 1985, Tetrahedron, 41 :5503-06 (hereby incorporated by reference) using a suspension of sodium methoxide in THF for 1 hour at room temperature (FIG. 13, step iv). The reaction was quenched by neutralization to yield the free 2'-OH group of compound 41.
  • step v The 2'-OH group of compound 41 was methylated by reaction with NaH and methyl iodide in THF at 0°C (step v) to yield compound 42.
  • the silyl group was removed from the 3'-OH group with nBu 4 F by the method of Perlikova 2014 and the 3'-OH group was butyrlated (step v) to produce the secoguanine compound 43 after removal of the DMTr protecting group with acid (CF3CO2H, step vi).
  • the trinucleotide cap analog is produced by the method described in Example 8.
  • a mixture of ammonium salt of 2'-OMe-m 6 Ap-seco-2'-OMeG 5'-monophosphate, compound 53 (produced in Example 16), four equivalents of a sodium salt of m 7 GDP-EVI (compound 1 produced in Example 1), and ZnC12 in DMF is stirred for 2 days at room temperature.
  • the reaction is quenched by addition of water to yield m 7 G(5')pppm 6 2'OMeAp- seco-2'OMeG (compound 54).
  • guanosine is isobutyrated at the N 2 position and crystallized from water to give N 2 -isobutyrylguanosine, and the 5'-hydroxy group is protected with a DMTr group (FIG. 16, step i) according to the method of WO 99/14266 to yield compound 49.
  • Second, 2'- and 3' hydroxy groups are subject to isobutyrylation, and the DMTr group is removed by treatment with 5% trichloroacteic acid to produce 2'-0-isobutyryl,3'-0-isobutyryl,N 2 - isobutyrylguanosine, compound 50 (FIG. 16, step ii).
  • compound 6 (5'0-DMT-2'0-Me-N 6 benzoyl- AMP-PhCl, Example 2) is combined with with isobutyrated guanosine compound 50 (Example 15) by the method of Lewdorowicz 2007.
  • Compound 6 is mixed with an equivalent of isobutyrated guanosine compound 50 in anhydrous acetonitrile. The mixture is dried by evaporation.
  • the 5'-hydroxy group of compound 52 is phosphorylated according to the method of Lewdorowicz 2007 (step ii).
  • Phosphorus trichloride oxide in trimethyl phosphate is cooled to 4°C and the 5'-0-guanine-adenine dinucleotide-3'-0 intermediate is added and stirred at 4°C for 3 hours.
  • Tetraethylammoniuum bromide (TEAB) is added to neutralize the mixture to produce p-2'-OMe-ApG dinucleotide (FIG. 18, compound 53).
  • Trinucleotide cap analog m 7 G(5')ppp-2'OMeApG (compound 54 of FIG. 19).
  • the trinucleotide cap analog is produced by the method of Lewdorowicz 2007.
  • a mixture of ammonium salt of pApG (compound 53 produced in Example 18), four equivalents of a sodium salt of m 7 GDP-IM (compound 3 produced in Example 1), and ZnCh in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield m 7 G(5')ppp-2'OMeApG (compound 54).
  • in vitro transcription was performed using the standard protocol (see Table, below). All of components were mixed, and T7 RNA polymerase (E2040 from NEB) was added in the reaction mixture. The transcription reaction was incubated for 2 hrs at 37C. After 2 hrs of reaction time, DNASEI (NEB) and buffer were added to the transcription reaction, and incubated for 15 mins at 37C. The crude of reaction mix was purified using RNA purification kit (Macherey-Nagel). [0142]
  • RNA purification kit Macherey-Nagel. The RNA was denatured at 65 °C for 5 min and then snap chilled to relieve any secondary conformations.
  • RNA in 700 1 mg denatured RNA in 700 [iL of nuclease-free water was used along with 100 ⁇ ⁇ 1 (10x) capping buffer, 50 uL (10 mM) GTP, 50 uL (4 mM) SAM, 50 uL of (10 units ⁇ )
  • Vaccinia capping enzyme and 50 ⁇ ⁇ of mRNAcap2'-0-methyltransferase at (50 units ⁇ L) were combined and incubated at 37 °C for 1 h.
  • the mixture capped mRNA was purified using RNA purification kit (Macherey-Nagel).
  • RNA purification kit Macherey-Nagel.
  • m 7 G(5')p3-RNA were delivered 0.3 mg/kg i.v. into 12-16 weeks old male mice. Blood samples were collected at 6 hours post dose, and plasma was isolated. Protein expression was performed using ELISA (e.bioscience). Results are shown in FIG. 16.

Abstract

What is described is a trinucleotide cap analog comprising m 7G(5')p3-N1pN2 for increased efficiency of in vitro transcription of m7G(5')p3-RNA, wherein m7G is N7- methylguanosine or analog, (5')p3 is a 5',5'-triphosphate bridge, and N1 or N2 or both ribonucleotide analogs linked to each other by a phosphate, p, and wherein the trinucleotide cap analog increases the efficiency of in vitro transcription.

Description

TRINUCLEOTIDE MRNA CAP ANALOGS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Patent Application
No. 62/410,325, filed October 19, 2016, the contents of which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
[0002] The description herein is directed to trinucleotide cap analogs for improved in vitro mRNA synthesis and translation of m7G(5')p3-RNA.
BACKGROUND
[0003] Eukaryotic mRNAs have a cap structure at their 5'-termini. The cap consists of 7-methyl guanosine (m7G) and a triphosphate bridge, ppp (p3), linking the 5ΌΗ of m7G to the 5ΌΗ of the 5'-terminal nucleotide, N, denoted m7G(5')pppN (m7G(5')p3N). In eukaryotic cells, the cap structure participates in assembly of the translation initiation complex by binding eukaryotic translation initiation factor 4E (eIF-4E).
[0004] Although m7G(5')p3 can be used to initiate transcription with T7 or SP6 DNA- dependent RNA polymerase in vitro, it has the disadvantage of having to compete with guanine nucleotide (G) as the initiating nucleophile for transcriptional elongation. As a result of this competition, less than half of mRNA produced in vitro have a cap structure at their 5' termini.
[0005] Dinucleotide m7G(5')p3(5')G, in which a guanine nucleotide (G) is linked via its 5ΌΗ to the triphosphate bridge, has been used as an initiator of transcription. This dinucleotide has the disadvantage that the 3'-OH of either the m7G or G moiety serves as the initiating nucleophile for transcriptional elongation that results in synthesis of two isomeric RNAs of the form m7G(5')p3G(pN)n and G(5')p37G(pN)n, with one third to one half of the caps oriented in the reverse direction, depending upon the ionic conditions of the transcription reaction. Further improvement of the orientation of the cap during in vitro transcription is possible using cap analogues that replace the 3'-OH group with hydrogen or -OCH3 (US 7,074,596; Kore, 2006, Nucleotides, Nucleotides, and Nucleic Acids, 25: 307-14, and Kore, 2006, Nucleotides,
Nucleotides, and Nucleic Acids, 25: 337-40).
[0006] Dinucleotide GG cap analogs m7G(5')p3G and 3'-OMe-m7G(5')p3G (ARCA) are sold commercially by TriLink BioTechnology, MilliporeSigma, ThermoFisher Scientific, and New England BioLabs Inc. 3'-OMe-m7G(5')p3G (ARCA) is incorporated during transcription without reversal to G(5')p3 m7G.
[0007] Trinucleotide cap analogs were disclosed by Ishikawa, 2009, Nucleic Acid Symp. Ser., 53 : 129-30. These are
• m7G(5')p3ApG, corresponding to the terminal trinucleotide of plant RNA;
• m7G(5')p3AmpG (Am is adenine with a 2'OMe-ribose), corresponding to the terminal trinucleotide of animal RNA;
• m7G(5')p3m6AmpG (m6A is N6-methyladenine), corresponding to the terminal trinucleotide of mammal RNA; and
• m7G(5')p3m6ApG, an unnatural trinucleotide.
Ishikawa discloses that translational efficiency in a rabbit reticulocyte lysate system is greatest with mRNA transcribed with an animal-type, followed by a mammalian-type, the unnatural, and the plant-type cap structures, respectively, and that G(5')p3Ampm7G-RNA, a result of transcribing in a reverse orientation, was not obtained. Id.
[0008] In view of the disclosure of these publications, there remains a need to identify modified cap structures that improve the efficiency of in vitro transcription.
SUMMARY
[0009] What is described herein is a trinucleotide cap analog consisting of m7G(5')p3- NipN2, in which a m7G ribonucleotide is linked at its 5'-OH to a triphosphate bridge (p3), wherein the triphosphate bridge is linked to a 5'-OH of ribonucleotide Ni, wherein Ni is linked via its 3'-OH to a phosphate, wherein the phosphate is linked to a 5'-OH of a second
ribonucleotide N2, and wherein Ni or N2 or both consist of a modified base or a modified ribose. The trinucleotide cap analogs described herein provide improved transcriptional efficiency for in vitro synthesis of capped mRNA, m7G(5')p3-RNA.
[0010] One aspect of the description is a compound of formula m7G(5')p3(5')NipN2, wherein m7G is a ribonucleotide consisting of N7-methylguanine and a ribose; wherein
(5')ρ3(5') is a 5' to 5' triphosphate linkage, and
wherein Ni and N2 are ribonucleotides, wherein one or both of Ni and N2 consist of a base selected from N6-methyladenine, N^methyladenine, pseudouruacil, N1- methylpseudouracil, 5-iodouracil, 4-thiouracil, 2-thiouracil, 5-methyluracil, pseudoisocytosine, 5-methoxycytosine, 2-thiocytosine, 5-hydroxycytosine, N4- methylcytosine, 5-hydroxymethylcytosine, hypoxanthine, N^methylguanine, O6- methylguanine, 1-methyl-guanosine, N2-methyl-guanosine (m2G), N2,N2-dimethyl- guanosine (m2'2G), 2-methyl-2'-0- methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-0- methyl-guanosine (m2,2Gm), l-methyl-2'-0-methyl-guanosine, N2,N7-dimethyl-2'-0- methyl-guanosine (m2,7Gm), or isoguanineadenine; and a ribose, a bicyclic (LNA) ribose, a seco (UNA) ribose, or a modified ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent; and
wherein the m7G ribonucleotide is linked at its 5'-OH to the triphosphate bridge, wherein the triphosphate bridge is linked to a 5'-OH of the Ni ribonucleotide, wherein Ni nucleotide is linked via its 3'-OH to a phosphate, p, wherein the phosphate is linked to a 5'-OH of the N2 ribonucleotide;
or a salt or solvated form thereof.
[0011] One embodiment of m7G(5')p3(5')NipN2 is wherein Ni is a ribonucleotide consisting of adenine, uridine, guanine, or cytidine, preferably adenine.
[0012] Another embodiment of m7G(5')p3(5')NipN2 is wherein N2 consists of N1- methylguanine, 06-methylguanine, 1-methyl-guanosine, m2G, m2,2G, m2Gm, m2,2Gm, 1-methyl- 2'-0-methyl-guanosine, m2,7Gm, or isoguanineadenine.
[0013] Another embodiment of m7G(5')p3(5')NipN2 is wherein N2 consists of N1- methylguanine, 06-methylguanine, or isoguanineadenine
[0014] Another embodiment of m7G(5')p3(5')NipN2 is wherein Ni consists of a LNA, a UNA, or a ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent.
[0015] Another embodiment of m7G(5')p3(5')NipN2 is wherein N2 is a ribonucleotide consisting of adenine, uridine, guanine, or cytidine, preferably guanine. [0016] Another embodiment of m7G(5')p3(5')NipN2 is wherein N2 is a ribonucleotide consisting of a LNA, a UNA, or a ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent.
[0017] Another embodiment of m7G(5')p3(5')NipN2 consists of m7G(5')p3AmpGm, wherein Am is 2'OMe-adenine and Gm is 2'OMe-guanine.
[0018] Another embodiment of m7G(5')p3(5')NipN2 consists of m7G(5')p3m6AmpGm, wherein 6mAm is 2'0Me-N6methyladenine and Gm is 2'OMe-guanine.
[0019] Another embodiment of m7G(5')p3(5')NipN2 consists of m7G(5')p3m6AmpGLNA, wherein 6mAm is 2'0Me-N6methyladenine and GLNA is guanine bicyclic (LNA)-ribose. Another embodiment is wherein at least one ribose of the m7G, Ni, or N2 ribonucleotide is a LNA.
[0020] Another embodiment of m7G(5')p3(5')NipN2 consists of m7G(5')p3m6AmpGuNA, wherein 6mAm is 2'0Me-N6methyladenine and GUNA is guanine seco(UNA)ribose. Another embodiment is wherein at least one ribose of m7G, Ni, or N2 ribonucleotide is a UNA.
[0021] Another embodiment of m7G(5')p3(5')NipN2 is, wherein at least one ribose of m7G, Ni, or N2 ribonucleotide is substituted by a 2'-Cl-C6-alkoxy, preferably 2'-OMe.
[0022] Another embodiment of m7G(5')p3(5')NipN2 is wherein the triphosphate bridge consisting of 1, 2, or 3 phosphorothioate groups.
[0023] Another embodiment of m7G(5')p3(5')NipN2 is wherein the compound increases the yield of 5'-capped transcripts produced by in vitro transcription compared to ACRA, for example, transcription is mediated by T7 RNA polymerase or T6 RNA polymerase.
[0024] Another aspect of the description is a compound of formula m7G(5')ppp-NipN2, wherein m7G is a ribonucleotide consisting of N7-methylguanine and a ribose, wherein ppp is a 5' to 5' triphosphate linkage; wherein Ni and N2 are ribonucleotides, wherein one or both of Ni and N2 ribonucleotides consist of a base selected from adenine, uracil, cytosine, or guanine; and a bicyclic (LNA) ribose, a seco (UNA) ribose, or a modified ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent; and
wherein the m7G ribonucleotide is linked at its 5'-OH to the triphosphate bridge, wherein the triphosphate bridge is linked to a 5'-OH of the Ni ribonucleotide, wherein Ni nucleotide is linked via its 3'-OH to a phosphate, p, wherein the phosphate is linked to a 5'-OH of the N2 ribonucleotide; or a salt or solvated form thereof.
[0025] In one aspect of the description, the m7G ribonucleotide of the trinucleotide cap analog is modified so that the base is substituted with hypoxanthine, rr^G, m6G, or isoguanine. In another aspect, one or both of the 2'-OH or the 3ΌΗ groups of the ribose group of the m7G ribonucleotide are substituted by fluoro or C1-C6 alkoxy group, or the ribose is substituted by bicyclic (LNA) or seco (UNA) ribose. In either case, the Ni and N2 ribonucleotides each consists of a base independently selected from adenine, uracil, cytosine, guanine, or an analog thereof, and a sugar selected from ribose, modified ribose, bicyclic ribose, or seco ribose.
[0026] Another aspect of the description is a method of synthesizing mRNA in vitro from DNA by using the trinucleotide cap analog according to description herein to initiate transcription. In preferred embodiments, the in vitro transcription uses a DNA-dependent RNA polymerase, e.g., commercially available bacteriophage T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase.
[0027] Another aspect of the description is mRNA produced by in vitro transcription using the trinucleotide cap analog described herein. A preferred embodiment is an mRNA produced the description herein that initiates translation of a protein. Another preferred embodiment is an mRNA produced by the methods herein that suppresses translation of a protein. Another embodiment is a pharmaceutical composition comprising the mRNA described herein and pharmaceutical excipients. In a preferred embodiment, the pharmaceutical composition comprises the mRNA encapsulated in a liposomal nanoparticle.
[0028] Another aspect of the description is a method of treating a disease, comprising administering the pharmaceutical composition described herein to a subject in need thereof.
[0029] Another aspect of the description is a kit comprising the trinucleotide cap analog described herein. In a preferred embodiment, the kit comprises a T7 RNA polymerase, a T3 RNA polymerase, or a SP6 RNA polymerase.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG. 1 shows synthesis of m7GDP-IM (3) from GDP (1) by step i to
intermediate m7GDP (2) and further imidazole addition at step ii.
[0031] FIG. 2 shows synthesis of 5'-0-DMT-2'0-Me-N6benzoyl-AMP-PhC (6) from 2'OMe-adenosine (4) to first form a TMS-modified, benzoyl-m6-2'-OMe-adenosine which is benzoylated, then desilylated, and further protected as a DMTr ether (5) at step i. The introduction of the phosphate moiety (step ii) then gives 6.
[0032] FIG. 3 shows synthesis of 2'-0-Me,3'-0-isobutyryl,N2-isobutyrylguanosine (9) from 2'OMe-guanosine (7) to produce intermediate N2-isobuyryl-2'-0-methylguanosine (8) in step i, in which the 5'-OH is protected as a DMTr ether, then the 3'-OH is isobutyrylated and finally the DMTr group is removed in step ii to give 9.
[0033] FIG. 4 shows synthesis of protected 2'-OMeAp-2'-OMeG dinucleotide (10) in step i by reaction of 3'-p-2'-OMeA (6) with 2'OMe guanosine (9).
[0034] FIG. 5 shows removal of the protective groups of 2'0MeAp2'0MeG
dinucleotide (10) in two steps: (i) to produce a 2'-OMeA-2'-OMeG dinucleotide compound 11 and phosphate introduction (ii) to produce 2'0MeAp2'0MeG dinucleotide 5 '-monophosphate (12).
[0035] FIG. 6 shows synthesis of m7G(5')ppp2'OMeAp2'OMeG (13) by reaction (i) of the ammonium salt of pApG (12) with the sodium salt of m7GDP-IM (3).
[0036] FIG. 7 shows synthesis of m6-benzoyl-2'-OMe-AMP-PhCl (18) from 2'OMe- adenosine (14) by first producing intermediate 15 (i), converting to intermediate 16 (ii), forming TMS-modified, mono-benzoylated m62'OMe-adenosine which is desilylated to give (17) (iii), and protection of the 5'-OH as a DMTr ether followed by phosphate introduction (iv) gives 18.
[0037] FIG. 8 shows formation of dinucleotide m62'OMeAp2'OMeG (21) by combining benzoyl-3'-p- m62'-OMeA (18) with protected 2'OMe adenosine (9) to produce intermediate m62'OMeAp2'OMeG dinucleotide (19) in step i. The protective groups of m62'OMeAp2'OMeG dinucleotide intermediate compound are removed (ii) to produce m62'OMeA-2'OMeG dinucleotide (20), which is phosphorylated (iii) to give 21.
[0038] FIG. 9 shows production of trinucleotide cap analog, m7G(5')ppp
m62'OMeAp2'OMeG (22) from the ammonium salt of pApG (21) and the sodium salt of m7GDP-IM (3).
[0039] FIG. 10 shows multistep synthesis of 2'-0,4'-C-methylene-linked bicyclic guanine nucleotide (32) from (3aS,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3- d][l,3]dioxole-5,5-diyl)dimethanol (23). First (i) the diol is reacted with MsCl to yield intermediate (24), which is hydrolyzed and acetylated (ii) to produce the two isomers of intermediate (25). This intermediate is fused (iii) with butyrated guanine to produce a guanine nucleotide (26) as a precursor (iv) to production of bicycle guanine nucleotide 27. The 5'OMs of bicyclic guanine 27 benzoylated (v) to produce benzoate-intermediate 28, and is then hydrolyzed (vi) to produce compound 29 having a free 5ΌΗ. Intermediate 29 is further deprotected (vii) to obtain compound 30 with free 3' and 5' OH groups. The 5' OH group of compound 30 is blocked by DMTrCl (viii) to produce compound 31, which is acylated (viii) to produce the locked guanyl nucleotide (32).
[0040] FIG. 11 shows synthesis of nucleotide m62'OMeAp-locked-2'OMeG (35) by (i) combining locked guanyl nucleotide (32) with benzoylated 3'-p-m62'-OMeA (18) to produce intermediate dinucleotide (33). The dinucleotide is deprotected (ii) to produce m62'OMeA- locked-2'-OMeG dinucleotide (34), which is phosphorylated (iii) to give 35.
[0041] FIG. 12 shows synthesis of trinucleotide cap analog, m7G(5')pppm62'OMeAp- locked-2'-OMeG (36) by combining the ammonium salt of m62'-OMeAp-locked-2'-OMeG dinucleotide 5'-monophosphate (35) with the sodium salt of m7GDP-IM (3)
[0042] FIG. 13 shows synthesis of 2'OMe-seco-3'-0-isobutyryl,N2-isobutyrylguanosine (43). The 5' OH group of N sobutyrylguanosine (37) is blocked with DMTrCl to produce intermediate 38 (i), which is converted (ii) to an "unlocked" form, 2'-0-benzoylated secoguanine (39). The 3'-OH group of the 2'-0-benzoylated secoguanine is protected by TBDMSC1 (40). The 2'-0-benzoyl group of intermediate 40 is removed (iv) to yield the free 2'-OH group (41), which is methylated (v) to yield intermediated 42. The silyl group is removed from the 3'-OH of intermediate 42 and the 3-OH group is butyrylated (v) to produce secoguanine (43) after deblocking of the 5'-ODMTr ether.
[0043] FIG. 14 shows synthesis of p-2'-OMe-m6Ap-seco-2'-OMeG (46). Protected 2'0MeAp2'0MeG dinucleotide (44) is produced by combining 3'-p-2'-OMeA (18) with protected 2'-OMe secoguanosine (43) to produce intermediate 44 (i). The protective groups of
intermediate 44 are removed (ii) to produce a 2'-OMeA-2'-OMeG dinucleotide (45). The 5'- hydroxy group of the adenosine group is phosphorylated (iii) to produce 2'-OMe-m6Ap-seco-2'- OMeG 5'-monophosphate (46).
[0044] FIG. 15 shows synthesis of trinucleotide cap analog, m7G(5')pppm62'-OMeAp- seco-2'-OMeG (47) from ammonium salt of 2'-OMe-m6Ap-seco-2'-OMeG 5 '-monophosphate (46) and the sodium salt of m7GDP-IM (3). [0045] FIG. 16 shows expression of m7G(5')ppp-RNA transcribed from ARC CAP1 (m7G(5')p3AmpG); ARCA (3'-OMe-m7G(5')p3G); or VACCINIA, without ARC CAP1 or ARC A, by post-transcriptional capping by a vaccinia capping enzyme.
DETAILED DESCRIPTION
[0046] In order to increase the efficiency of in vitro transcription of m7G(5')p3-RNA, the present description provides a trinucleotide cap analog, m7G(5')p3(5')NipN2.
[0047] Definitions that follow will apply to the description herein. Whenever appropriate, terms used in the singular will also include the plural and vice versa. In the event that any definition set forth below conflicts with the usage of that word in any other document, including any document incorporated herein by reference, the definition set forth below shall always control for purposes of interpreting this specification and its associated claims unless a contrary meaning is clearly intended (for example in interpreting the document where the term is originally used). The use of "or" herein means "and/or" unless stated otherwise or where the use of "and/or" is clearly inappropriate. The use of "a" herein means "one or more" unless stated otherwise or where the use of "one or more" is clearly inappropriate. The use of "comprise," "comprises," "comprising," "include," "includes," and "including" are interchangeable and not intended to be limiting.
[0048] As used herein, "Me" means "CH3", and "OCft" or "OMe" denotes an oxygen atom bound to a methyl group, "CHO" denotes a carbon atom, C, bonded to a hydrogen atom, H, and double-bonded to an oxygen atom, O, (0=CH— ) and "Et" denotes "C2H5".
[0049] "Cap" herein means a non-extendible trinucleotide that facilitates translation or localization, and/or prevents degradation of an RNA transcript when incorporated at the 5' end of an RNA transcript. It consists in nature of the modified base 7-methylguanosine joined in the opposite orientation, 5' to 5' rather than 5' to 3', to the rest of the RNA molecule via three phosphate groups i.e., PI-guanosine-5'-yl P3-7-methylguanosine-5'-yl triphosphate
(m7G5'ppp5'G).
[0050] "Hydrate" is a solvate wherein the solvent molecule is H2O.
[0051] A "cap analog" means a structural derivative of an RNA cap that may differ by as little as a single element. Cap analog is used for the synthesis of 5' capped RNA molecules in in vitro transcription reactions. Substitution of cap analog for a portion of the GTP in a transcription reaction results in the incorporation of the cap structure into a corresponding fraction of the transcripts. Capped mRNAs are generally translated more efficiently in reticulocyte lysate and wheat germ in vitro translation systems. In vitro transcripts must be capped for microinjection experiments because uncapped mRNAs are rapidly degraded. Cap analogs can also be used as a highly specific inhibitor of the initiation step of protein synthesis.
[0052] "Enzymatically incorporatable" means a nucleotide is capable of being enzymatically incorporated onto the terminus, e.g. 3' terminus, of a polynucleotide chain, or internally through nick-translation of a polynucleotide chain, through action of a template- dependent or template-independent polymerase enzyme. A nucleotide-5 '-triphosphate is an example of an enzymatically incorporatable nucleotide.
[0053] "Enzymatically extendable" or "3' extendable" means a nucleotide or polynuceotide that is capable of being appended to a nucleotide or polynucleotide by enzyme action. A polynucleotide containing a 3' hydroxyl group is an example of an enzymatically extendable polynucleotide.
[0054] A "locked nucleic acid" (LNA) means a ribonucleotide in which there is a bridge between the 2Ό and 4'C methylene bicyclonucleotide monomers.
[0055] A "nucleobase" means a nitrogen containing heterocyclic moiety nucleobase. Non-limiting examples of suitable nucleobases include: adenine, cytosine, guanine, thymine, uracil, or analogs thereof, e.g., 5-propynyl-uracil, 2-thio-5-propynyl-uracil, 5-methylcytosine, pseudoisocytosine, 2-thiouracil, 2-thiothymine, 2-aminopurine, N9-(2-amino-6-chloropurine), N9-(2,6-diaminopurine), hypoxanthine, N9-(7-deaza-guanine), N9-(7-deaza-8-aza-guanine) and N8-(8-aza-7-deazaadenine).
[0056] A "ribonucleotide" or "nucleotide" herein means a compound consisting of a nucleobase linked to the C- carbon of a ribose sugar or analog thereof. The ribose or analog may be substituted or unsubstituted. Substituted ribose sugars include, but are not limited to, those riboses in which one or more of the carbon atoms, preferably the 3 '-carbon atom, is substituted with one or more of the same or different substituents such as— R,— OR,— NRR or halogen {e.g., fluoro, chloro, bromo, or iodo), where each R group is independently— H, Ci-C6 alkyl or C6-Ci4 aryl or arylalkyl. Typically, when the nucleobase is A or G, the ribose sugar is attached to the N9-position of the nucleobase. When the nucleobase is C, T or U, the pentose sugar is attached to the ^-position of the nucleobase. Examples of ribose analogs include arabinose, 2'-0-methyl ribose, UNA, and LNA analogs.
[0057] A "ribonucleotide" means a phosphate ester of a ribonucleotide as a monomer unit or within a polynucleotide.
[0058] A "nucleotide triphosphate" means a nucleotide with a triphosphate ester group at the 5' position.
[0059] "Alkyl", "CI, C2, C3, C4, C5 or C6 alkyl" or "C1-C6 alkyl" is intended to include CI, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or e branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include CI, C2, C3, C4, C5 and C6 alkyl groups. Examples of alkyl include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl or n-hexyl.
[0060] In certain embodiments, a straight chain or branched alkyl has six or fewer carbon atoms (e.g. , C1-C6 for straight chain, C3-C6 for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms. Ribonucleotides and/or ribonucleotides comprise ribose or a ribose analog.
[0061] "Ribose analog" includes, e.g., substituted or unsubstituted furanoses having more or fewer than 5 ring atoms, e.g., erythroses and hexoses and substituted or unsubstituted 3- 6 carbon acyclic sugars (e.g., UNA). Typical substituted furanoses and acyclic sugars are those in which one or more of the carbon atoms are substituted with one or more of the same or different— R,— OR,— NRR or halogen groups, where each R is independently— H, (Ci-C6) alkyl or (C1-C14) aryl. Examples of substituted furanoses having 5 ring atoms include but are not limited to 2'-deoxyribose, 2'-(Ci-C6)alkylribose, 2'-(Ci-C6)alkoxyribose, 2'-(Cs- Ci4)aryloxyribose, 2',3'-dideoxyribose, 2',3'-didehydroribose, 2'-deoxy-3'-haloribose, 2'-deoxy- 3'-fluororibose, 2'-deoxy-3'-chlororibose, 2'-deoxy-3'-aminoribose, 2'-deoxy-3'-(Ci- C6)alkylribose, 2'-deoxy-3'-(Ci-C6)alkoxyribose, 2'-deoxy-3'-(C5-Ci4)aryloxyribose, 3'-(Ci- C6)alkylribose-5 '-triphosphate, 2'-deoxy-3-'-(Ci-C6)alkylribose-5'-triphosphate, 2'-deoxy-3'-(Ci- C6)alkoxyribose-5 '-triphosphate, 2'-deoxy-3'-(C5-Ci4)atyloxyribose-5 '-triphosphate, 2'-deoxy-3'- haloribose-5 '-triphosphate, 2'-deoxy-3'-aminoribose-5 '-triphosphate, 2',3'-dideoxyribose-5'- triphosphate or 2',3'-didehydroribose-5 '-triphosphate. Further sugar analogs also include so called locked nucleic acids (LNAs) having the structure
Figure imgf000012_0001
and those described in WO 99/14226 and Koskin, 2001, J Org Chem, 66:8504-12 (incorporated
H
Figure imgf000012_0002
herein by reference) and unlocked ribonucleic acid (UNA) having the structure
and those described in US 9297009 and US 9051570 (incorporated herein by reference).
[0062] "Polynucleotide", "oligonucleotide" and "nucleic acid" mean single stranded or double stranded polymers of nucleotide monomers, including ribonucleotides (RNA) and 2'- deoxyribonucleotides (DNA) linked by internucleotide phosphodiester bond linkages. A polynucleotide may be composed entirely of deoxyribonucleotides, entirely of ribonucleotides or chimeric mixtures thereof.
[0063] "Substituted" means substitution with specified groups other than hydrogen, or with one or more groups, moieties or radicals which can be the same or different, with each, for example, being independently selected.
[0064] The trinucleotide compounds of described herein form salts that are also within the scope of this disclosure. Reference to a trinucleotide compound herein is understood to include reference to salts thereof, unless otherwise indicated.
[0065] "Salt(s)" mean acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a trinucleotide compound contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. The salts can be
pharmaceutically acceptable {i.e., non-toxic, physiologically acceptable) salts, although other salts are also useful. Salts of the trinucleotide compounds may be formed, for example, by reacting the trinucleotide compounds with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
[0066] Exemplary acid addition salts include acetates, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecyl sulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, benzenesulfonates, toluenesulfonates, nitrobenzene sulfonates, 2- napthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates, sulfonates (such as those mentioned herein), tartarates, thiocyanates, toluenesulfonates (also known as tosylates) undecanoates, and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds. These disclosures are incorporated herein by reference herein.
[0067] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines,
dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N- methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, trialkyl amines such as triethyl amine, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), allylic and propargylic halides such as l-bromo-2-propene and l-bromo-2-propyne, and others.
[0068] All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the disclosure and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the disclosure.
[0069] "Solvate" means a physical association of a trinucleotide compound of this disclosure with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. Solvate encompasses both solution- phase and isolatable solvates. Non-limiting examples of suitable solvates include water, ethanolates, methanolates, and the like. Trinucleotide compounds of the disclosure can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for the purposes of this disclosure.
[0070] Trinucleotide compounds of the disclosure, and solvates thereof, may exist in their tautomeric form. All such tautomeric forms are contemplated herein as part of the present disclosure.
[0071] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present trinucleotide compounds (including those of the salts, solvates and prodrugs of the trinucleotide compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this disclosure. Individual stereoisomers of the trinucleotide compounds of this disclosure may, for example, be
substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the trinucleotide compounds herein can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, or racemates of the disclosed trinucleotide compounds.
[0072] The trinucleotide compounds of the disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such trinucleotide compounds. Unnatural proportions of an isotope may be defined as ranging from the amount found in nature to an amount consisting of 100% of the atom in question. For example, the trinucleotide compounds may incorporate radioactive isotopes, such as, for example, tritium (3H), iodine-125 (125I) or carbon-14 (14C), or non-radioactive isotopes, such as deuterium (2H), carbon- 13 (13C), or isotopes of nitrogen, oxygen and sulfur. Such isotopic variations can provide additional utilities to those described elsewhere within this application. For instance, isotopic variants of the trinucleotide compounds of the invention may find additional utility, including but not limited to, as diagnostic and/or imaging reagents, or as cytotoxic/radiotoxic therapeutic agents. Additionally, isotopic variants of the trinucleotide compounds of the invention can have altered pharmacokinetic and pharmacodynamic characteristics which can contribute to enhanced safety, tolerability or efficacy during treatment. All isotopic variations of the trinucleotide compounds of the description herein, whether radioactive or not, are intended to be encompassed within the scope of the description herein.
[0073] "Inhibitors" and "antagonists", or "activators" and "agonists" mean inhibitory or activating molecules, respectively, for example, for the activation of, e.g., a ligand, receptor, cofactor, gene, cell, tissue, or organ. Inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell. Activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up- regulate, e.g., a gene, protein, ligand, receptor, or cell. An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity. An "agonist" is a molecule that interacts with a target to cause or promote an increase in the activation of the target. An "antagonist" is a molecule that opposes the action(s) of an agonist. An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist.
[0074] The "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the
modulation of activities of other molecules; and the like.
[0075] "Proliferative activity" means an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis. mRNA synthesis
[0076] The trinucleotide cap analogs disclosed herein are used for improving the synthesis of 5' capped RNA molecules in in vitro transcription reactions. Substitution of cap analog for a portion of the GTP in a transcription reaction results in the incorporation of the cap structure into a corresponding fraction of the transcripts.
[0077] Transcription of RNA usually starts with a nucleotide triphosphate (usually a purine, A or G). When transcription occurs in vitro, it typically includes a phage RNA polymerase such as T7, T3 or SP6, a DNA template containing a phage polymerase promoter, nucleotides (ATP, GTP, CTP and UTP) and a buffer containing magnesium salt. The synthesis of capped RNA includes the incorporation of a cap {e.g., m7GpppG) or a cap analog (such as those described herein) in the transcription reaction. Excess cap to GTP {e.g., 4: 1) increases the opportunity that each transcript will have a 5' cap. The mMESSAGE mMACHINE® SP6 Transcription Kit and SP7 Ultra Kit (ThermoFisher Scientific) recommends this ratio and will typically yield 80% capped RNA to 20% uncapped RNA, although total yields of total RNA are lower as GTP concentration becomes rate limiting as GTP is necessary for the elongation of the transcript.
[0078] Capped mRNAs are generally translated more efficiently in reticulocyte lysine and wheat germ in vitro translation systems. It is important that in vitro transcripts be capped for microinjection experiments because uncapped mRNAs are rapidly degraded. Cap analogs are also used as a highly specific inhibitor of the initiation step of protein synthesis.
[0079] The 5' cap structure enhances the translation of mRNA by helping to bind the eukaryotic ribosome and assuring recognition of the proper AUG initiator codon. This function may vary with the translation system and with the specific mRNA being synthesized. The consensus sequence 5'-GCCACCAUGG-3', also known as the "Kozak" sequence, is considered to be the strongest ribosomal binding signal in eukaryotic mRNA. For efficient translation initiation, the key elements are the 5' G residue at the +1 position and the A residue at the 3' position of the mRNA.
[0080] The mRNA can be transfected into a cell to be translated intracellularly.
Methods of transfection are known to those of skill in the art and include microinjection, electroporation, chemical treatments and the like. Cells for use in in vivo translation include any patient cell for which it is desired to express a protein of interest. Cells include hematopoietic cells (e.g., T cells, dendritic cells, macrophages, etc.), bone marrow cells, tissue culture cells, germ cells, and the like.
[0081] Compositions comprising modified capped RNA as described herein can be used for in vitro transcription, in vitro translation, and in vivo translation, for example. Current biotechnology efforts for in vitro, in situ, and in vivo protein production will also benefit from these methods and compositions. Further, compositions provided herein are useful for therapeutic purposes. For example, the present technology may be useful for generating vaccines against infectious diseases or cancers. Alkyne-derivatized capped RNA can be used to produce non-infectious particles of Venezuelan Equine Encephalitis virus containing an RNA encoding immunogen. These non-replicating viral particles can be injected into humans where they can enter host cells. Once in the host cell, the viral particles dissociate and the mRNA encoding the immunogen is translated into protein. These proteins can induce an immune response. These types of vaccines are expected to be useful for human immunodeficiency virus (HIV), feline immunodeficiency virus, human papilloma virus type 16, tumors, lassa virus, Ebola virus, Marburg virus, anthrax toxin from Bacillus anthraces, and botulinum toxin. These vaccine strategies can require large quantities of capped RNA. The present methods facilitate such synthesis and subsequent purification of capped RNA so as to make these vaccines commercially feasible. As well, strategies to increase the percentage of full length capped RNA in a transcription reaction leading to a more homogenous product will be preferred in the vaccine industry as highly pure components are usually required for human use. In addition, researchers prefer to use products that are as pure as possible to minimize the number of variables in an experiment. As well, the purer the product, the more potent it is.
[0082] Such oligomers or oligonucleotides may be prepared by solid state synthesis or by other means known to those skilled in the art. For example, 2'-0-alkyl guanosine
phosphoramidites and derivatives thereof may be incorporated into oligonucleotides using standard phosphoramidite chemistry. Incorporation of 2'-0-alkyl guanosine nucleotides may confer desirable characteristics to an oligonucleotide such as enhanced resistance to nuclease.
[0083] "Oligonucleotide" or "oligomer" as used herein means a polynucleotide formed from naturally occurring bases and furanosyl groups joined by native phosphodiester bonds. Oligonucleotides of the description herein will, of course, comprise at least one 2'-0-alkyl guanosine or derivative thereof. Thus, this term effectively refers to naturally occurring species or synthetic species formed from naturally occurring subunits or their close homologs. The term "oligonucleotide" or "oligomer" may also refer to moieties which have portions similar to naturally occurring oligonucleotides but which have non-naturally occurring portions. Thus, oligonucleotides may have altered sugars, altered base moieties, or altered inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur-containing species which are known for use in the art. In accordance with some preferred embodiments, at least some of the phosphodiester bonds of the oligonucleotide have been substituted with a structure which functions to enhance the stability of the oligonucleotide or the ability of the oligonucleotide to penetrate into the region of cells where the messenger RNA is located. It is preferred that such substitutions comprise phosphorothioate bonds, phosphotriesters, methyl phosphonate bonds, short chain alkyl or cycloalkyl structures or short chain heteroatomic or heterocyclic structures. Other preferred substitutions are CH2— NH— O— CH2, CH2— N(CH3)— O— CH2, CH2— O— N(CH3)— CH2, CH2— N(CH3)— N(CH3)— CH2 and O— N(CH3)— CH2— CH2 structures where phosphodiester intersugar linkage is replaced by the substitutions. Also preferred are morpholino structures. In accordance with other preferred embodiments, the phosphodiester bonds are substituted with other structures which are, at once, substantially non-ionic and non-chiral, or with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in practice of the invention.
[0084] Oligonucleotides may also include species which include at least some modified base forms. Thus, purines and pyrimidines other than those normally found in nature may be so employed. Suitable bases include modifications on the furanosyl portion of the nucleotide subunits, in addition to 2'-0-alkyl modifications of the description herein, may also be effected, as long as the essential tenets of this invention are adhered to. Examples of such modifications are 2'-halogen-substituted nucleotides. Some specific examples of modifications at the 2' position of sugar moieties which are useful in the description herein are OH, SH, SCH3, F, OCN, 0(CH2)n H2, CI, Br, CN, CF3, OCF3, S— , OC1-OC12, O-alkenyl, O-alkynal, or N-alkyl; S— or N-alkenyl; SOCH3, S02CH3; ON02; N02; N3; H2; heterocycloalkyl; heterocycloalkaryl;
aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. Sugar mimetics such as cyclobutyls may also be used in place of the pentofuranosyl group. Oligonucleotides may also comprise other modifications consistent with the spirit of this invention. Such oligonucleotides are best described as being functionally interchangeable with yet structurally distinct from natural oligonucleotides. All such oligonucleotides are comprehended by this invention so long as they effectively function as subunits in the oligonucleotide.
[0085] Preferably oligonucleotides of the description herein are from about 6 to about 50 nucleotides in length. In still more preferred embodiments of the description herein oligonucleotides are from about 12 to about 20 nucleotides in length.
[0086] Intercalators are molecules which insert themselves between neighboring bases of an oligonucleotide, e.g., acridine.
[0087] Reporter molecules are molecules which may aid in the identification of a molecule, either visually or otherwise. For example, biotin and various fluorophores are effective reporter groups.
[0088] Conjugates, or bifunctional linkers effectively join two groups. Some conjugates are commercially available such as biotin or 3' maleimidobenzoyl-N-hydroxy-succinimide.
[0089] Pharmacodymanic property improvement means, in this context, improved oligonucleotide uptake, enhanced oligonucleotide resistance to degradation, and/or strengthened sequence-specific hybridization with RNA. Such groups do not initiate chemical reactions.
Groups that enhance the pharmacodynamic properties of an oligonucleotide preferably include alkyl chains, polyamines, ethylene glycols, polyamides, alkyl chains, aminoalkyl chains and amphipathic moieties. Pharmacokinetic property improvement means improved oligonucleotide uptake, distribution, metabolism or excretion.
[0090] Antisense therapy involves the use of oligonucleotides which are specifically hybridizable to target RNA or DNA. Oligonucleotides of the description herein are preferably specifically hydridizable with a target region. "Specifically hybridizable" means capable of forming a stable duplex with a target DNA or RNA. Upon binding to, or forming a stable duplex with, the target RNA or DNA, the antisense oligonucleotide can selectively inhibit the genetic expression of these nucleic acids or can induce some other events such as destruction of a targeted RNA or DNA or activation of gene expression. Destruction of targeted RNA can be effected by RNase H activation or by linking strand cleavers to the oligonucleotide. [0091] In some embodiments of the description herein the oligonucleotide portions of trinucleotide compounds of the description herein are at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%) complementary to a target sequence. In preferred embodiments of the description herein the oligonucleotide portions of trinucleotide compounds of the description herein are at least 60%), 70%, or 80%> complementary to a target sequence. 100% complementarity of the oligonucleotide portions of trinucleotide compounds of the description herein to a target sequence is most preferred. In preferred embodiments of the description herein, the
oligonucleotide portions may be specifically hybridizable with DNA or RNA from Candida, papilloma virus, Epstein Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, influenza virus and cytomegalovirus.
[0092] 2-O-alkyl guanosine containing oligonucleotides of the description herein may be used to modulate the production of protein by contacting a selected sequence of RNA or DNA coding for a selected protein with an 2'-0-alkyl guanosine containing oligonucleotide of the description herein having a sequence of nucleotide bases specifically hybridizable with said selected sequence of RNA or DNA coding for said protein.
[0093] The oligonucleotides of the description herein can be used in diagnostics, therapeutics and as research reagents. For therapeutic use, an animal having a disease characterized by the undesired production of a protein is contacted with an oligonucleotide of the description herein having a sequence of nucleotide bases specifically hybridizable with a selected sequence of RNA or DNA coding for said protein.
Pharmaceutical use
[0094] Another use of compositions described herein involves isolating dendritic cells (DCs) from a patient and then transfecting the dendritic cells with derivatized capped RNA as described herein encoding immunogen. The dendritic cells translate the derivatized capped RNA into at least one protein that induces an immune response against this protein.
[0095] Morse, 2002, Int J Gastrointest Cancer, 32: 1-6, discloses that immunotherapy with dendritic cells loaded with CEA capped RNA is safe and feasible for pancreatic cancer patients. Heiser, 2002, J Clin Invest, 109:409-17, discloses that introducing at least one single capped RNA species into immature dendritic cells induced a specific T-cell response. The cap analogs provided herein can be used for providing mRNAs for antigen delivery to DCs for the purpose of immunotherapy against cancer and infectious diseases. [0096] Other uses include reprogramming differentiated cells to pluripotency and/or to re-program pluripotent cells using capped RNA described herein to specifically differentiate cell types by continuous transfection of specific derivatized-capped mRNAs over a time-period necessary for changing the cell differentiation.
[0097] Trinucleotide compounds of the disclosure may be in the form of compositions suitable for administration to a subject. In general, such compositions are "pharmaceutical compositions" comprising at least one trinucleotide compound and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients. In certain embodiments, trinucleotide compounds of the disclosure are present in a therapeutically acceptable amount. The pharmaceutical compositions may be used in the methods of the description herein; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.
[0098] The pharmaceutical compositions of the description herein can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein. Furthermore, the pharmaceutical compositions may be used in combination with other therapeutically active agents or trinucleotide compounds as described herein in order to treat or prevent the diseases, disorders and conditions as contemplated by the description herein.
[0099] The description herein contemplates the administration of trinucleotide compounds of the disclosure, and compositions thereof, in any appropriate manner. Suitable routes of administration include oral, parenteral {e.g., intramuscular, intravenous, subcutaneous {e.g., injection or implant), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebroventricular), nasal, vaginal, sublingual, intraocular, rectal, topical {e.g., transdermal), sublingual and inhalation.
[00100] Trinucleotide compounds of the disclosure may be administered to a subject in an amount that is dependent upon, for example, the goal of administration {e.g., the degree of resolution desired); the age, weight, sex, and health and physical condition of the subject to which the formulation is being administered; the route of administration; and the nature of the disease, disorder, condition or symptom thereof. The dosing regimen may also take into consideration the existence, nature, and extent of any adverse effects associated with the agent(s) being administered. Effective dosage amounts and dosage regimens can readily be determined from, for example, safety and dose-escalation trials, in vivo studies (e.g., animal models), and other methods known to the skilled artisan.
[00101] In general, dosing parameters dictate that the dosage amount be less than an amount that could be irreversibly toxic to the subject (the maximum tolerated dose (MTD)) and not less than an amount required to produce a measurable effect on the subject. Such amounts are determined by, for example, the pharmacokinetic and pharmacodynamic parameters associated with ADME, taking into consideration the route of administration and other factors.
[00102] An effective dose (ED) is the dose or amount of an agent that produces a therapeutic response or desired effect in some fraction of the subjects taking it. The "median effective dose" or ED50 of an agent is the dose or amount of an agent that produces a therapeutic response or desired effect in 50% of the population to which it is administered. Although the ED50 is commonly used as a measure of reasonable expectance of an agent's effect, it is not necessarily the dose that a clinician might deem appropriate taking into consideration all relevant factors. Thus, in some situations the effective amount is more than the calculated ED50, in other situations the effective amount is less than the calculated ED50, and in still other situations the effective amount is the same as the calculated ED50.
[00103] The amount and frequency of administration of the trinucleotide compounds of this disclosure and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
Examples
[00104] Aspects of the present teachings may be further understood in light of the following examples, which should not be construed as limiting the scope of the present teachings in any way.
[00105] While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.
Example 1
[0106] 2-amino-9-((2S,3R,4S,5S)-3,4-dihydroxy-5-(((hydroxy((hydroxy(lH-imidazol- l-yl)phosphoryl)oxy)phosphoryl)oxy)methyl)tetrahydrofuran-2-yl)-7-methyl-6-oxo-6,9-dihydro- lH-purin-7-ium (m7GDP-IM, FIG. 1, compound 3). Synthesis of m7GDP-IM from GDP is done by a two-step process according to Pi ecyk, 2012, Tetrahedron Letters, 53 :4843-47 (hereby incorporated by reference), First, GDP (compound 1) is reacted with methyl iodide in DMSO to produce m7GDP (compound 2, step i). One equivalent of m7GDP is combined with 20 equivalents of imidazole, 2 equivalents of 2,2'-dithiophyridine, and triethylamine in anhydrous dimethylformamide (DMF) and stirred for 6-8 hours at room temperature (step ii). The imidazole product is precipitated from a solution of anhydrous sodium perchlorate in dry acetone and, after cooling to 4°C, the precipitate is filtered, washed in acetone, and dried overnight under vacuum to yield m7GDP-IM (compound 3).
Example 2
[0107] (2R,3S,4S,5R)-5-(6-benzamido-9H-purin-9-yl)-2-(hydroxy-DMT)-4- methoxytetrahydrofuran-3-yl (4-chlorophenyl) phosphate (5'-0-DMT-2'0-Me-N6benzoyl- AMP-PhCl, FIG. 2, compound 6) is prepared in two steps. First, commercially available 2'OMe- adenosine (compound 4) is reacted with benzoyl chloride in pyridine to acylate N6 by the method of Zhu, 2003, Synthetic Communications, 33 : 1233-43 (hereby incorporated by reference).
2'OMe-adenosine is reacted with 1.1 equivalents of TMSC1 per OH group together with 1.2 equivalents of benzoyl chloride to produce TMS-modified, benzoyl-m6-2'-OMe-adenosine. The TMSA groups are removed under aqueous acidic conditions in THF-TFA. Further, the 5'- hydroxy of benzoyl-m6-2'-OMe-adenosine is reacted with DMT to form an ether (step ii) (compound 5) according to the method of WO 99/14266 (hereby incorporated by reference) by preparing a anhydrous pyridine solution of the nucleotide, adding an excess of 4,4'- dimethoxytrityl chloride, stirring at room temperature for 2 hours, quenching the reaction with ice cold water, and extracting the product with DCM. The combined organic phases are washed with NaHC03-saturated water, brine, and dried Na2S04. Phosphorylated adenosine is produced from DMT protected compound 5 by the method of Lewdorowicz, 2007, Nucleotides,
Nucleotides, and Nucleic Acids, 26: 1339-48 (hereby incorporated by reference) by reaction with 4-chlorophenyl dichlorophosphate as a 3'-0-phosphorylating agent (step ii) to produce 5Ό- DMT-2'-0-Me-N6benzoyl-AMP-PhCl (compound 6).
Example 3
[0108] (2R,3S,4S,5R)-2-(hydr oxymethyl)-4-methoxy-5-(6-oxo-2-pr opionamido- 1,6- dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl isobutyrate (2'-0-Me,3'-0-isobutyryl,N2- isobutyrylguanosine; FIG. 3, compound 9). Compound 9 is synthesized by the method of US 7101993 (hereby incorporated by reference) from commercially available 2'OMe-guanosine (FIG. 7, step i). 2'-0-methylguanosine (compound 7) in pyridine is cooled in an ice bath and 6 equivalents of trimethylsilyl chloride (TMSC1) is added and mixed for 30 minutes, and isobutyryl chloride is added and stirred for 4 hours. Water is added and the mixture is stirred for 30 minutes and concentrated H4OH is added and the solution is evaporated in vacuo to produce the N2-isobuyryl-2'-0-methylguanosine compound 8. The 5'-hydroxy group is protected with a DMT group, the 3'-hydroxy group is subject to isobutyrylation, and the DMT group is removed by treatment with 5% trichloroacteic acid to produce protected 2'OMe guanine compound 9 (step ii).
Example 4
[0109] ((2R,3S,4S,5R)-3-(((((2R,3S,4S,5R)-5-(2-amino-6-oxo-l,6-dihydro-9H-purin- 9-yl)-3-hydroxy-4-methoxytetrahydrofuran-2-yl)methoxy)oxidophosphoryl)oxy)-5-(6- amino-9H-purin-9-yl)-4-methoxytetrahydrofuran-2-yl)methyl hydrogen phosphate
(p-2-'OMeAp-2'-OMeG, FIG. 5, compound 12). Protected 2'0MeAp2'0MeG dinucleotide, compound 10 (FIG. 4), was produced by combining 3'-p-2'-OMeA compound 6 (Example 2) with protected 2'-OMe guanosine compound 9 (Example 3) by the method of Lewdorowicz 2007. First, 3'-p-2'-OMeA compound 6 was mixed with an equivalent of 2'OMe guanosine compound 9 in anhydrous acetonitrile and the mixture was dried by evaporation. A solution of 2,4,6,-triisopropylbenzenesulfonyl chloride and N-methylimidazole in acetonitrile was added and the mixture was reacted for 4 hours to produce the protected 2'-OMeAp-2'-OMeG dinucleotide compound 10 (FIG. 4, step i).
[0110] The protective groups of 2'0MeAp2'0MeG dinucleotide compound 10 were removed (FIG. 5, step i) using known reactions, e.g., by a method selected from Lewdorowicz 2007; Huss, 1988, J Org Chem, 53 :499-506; Zhou, 1986, Tetrahedron, 42:4149-56; Reese, 1986, Tetrahedron Letters, 27:2291-94; Abramova, 2008, Biorg Med Chem, 16:9127-32; Abramova, 2013, Beilstein J Org Chem, 9:2898-909; Hashmi, 1994, Nucleotides & Nucleotides, 13 : 1059-67; Hsu, 1985, Nucleotides & Nucleotides, 4:377-89; Puech, 1988, J Med Chem, 31 : 1897-907 (hereby incorporated by reference) (FIG. 5, step i) were removed to produce a 2'-OMeA-2'- OMeG dinucleotide compound 11. The 5'-hydroxy group of the adenosine group was phosphorylated according to the method of Lewdorowicz 2007 (FIG. 5, step ii). Phosphorus trichloride oxide in trimethyl phosphate was cooled to 4°C and the 5'-0-guanine-adenine dinucleotide-3'-0 compound 10 was added and stirred at 4°C for 3 hours.
Tetraethylammoniuum bromide (TEAB) was added to neutralize the mixture to produce the 2'0MeAp2'0MeG dinucleotide 5'-monophosphate (FIG. 5, compound 12).
Example 5
[0111] Trinucleotide cap analog, m7G(5,)ppp2,OMeAp2'OMeG (FIG , compound 20). The trinucleotide cap analog is produced by the method of Lewdorowicz 2007. A mixture of ammonium salt of pApG (compound 19 produced in Example 7), four equivalents of a sodium salt of m7GDP-IM (compound 1 produced in Example 1), and ZnC12 in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield
m7G(5')ppp2'OMeAp2'OMeG (compound 20).
Example 6
[0112] 4-chlorophenyl ((2R,3S,4S,5R)-2-(0-DMT)-4-methoxy-5-(6-(N- methylbenzamido)-9H-purin-9-yl)tetrahydrofuran-3-yl) phosphate
(m6-benzoyl-2'-OMe-AMP-PhCl, FIG. 7 compound 18). Commercially available 2'OMe- adenosine compound 14 was diazotized in aqueous acetic acid with nitrous acid to give compound 15 (step i) by the method of Hyde, 2003, JMed Chem, 46: 1878-85 (hereby incorporated by reference). Compound 15 was converted to a compound 16 by the method of Miiller, 2015, J Med Chem, 58:6248-6263 (hereby incorporated by reference) (step ii). The m62'OMe-adenosine product (compound 16) was protected by the method of Zhu, 2003, Synthetic Communications, 33 : 1233-43 (hereby incorporated by reference) (step iii). The adenosine compound was reacted with 1.1 equivalents of TMSCl per hydroxy group together with 1.2 equivalents of benzoyl chloride to produce TMS-modified, mono-benzoylated m62'OMe-adenosine. The TMSA groups were removed under aqueous acidic conditions in THF-TFA to give compound 17 (step iii). The 5'-hydroxy was reacted with DMT-C1 to form an ether and the phosphorylated adenosine compound 18 was produced as in Example 2 by reaction with 4-chlorophenyl dichlorophosphate as a 3'-0-phosphorylating agent (FIG. 7, step iv) to produce benzoyl-3'-p- m62'-OMeA (compound 18).
Example 7
[0113] Dinucleotide ηι62ΌΜ6Αρ2ΌΜ6θ (compound 21, FIG 8) Compound 21 is produced by combining benzoyl-3'-p- m62'-OMeA compound 18 (Example 7) with protected 2'OMe adenosine compound 9 (Example 3) by the method of Lewdorowicz 2007. First, 3'-p-2'- OMeA compound 18 is mixed with 1 equivalent of 2'OMe guanosine compound 9 in anhydrous acetonitrile and the mixture is dried by evaporation. A solution of 2,4,6,- triisopropylbenzenesulfonyl chloride and N-methylimidazole in acetonitrile is added and reacted for 4 hours to produce the protected m62'OMeAp2'OMeG dinucleotide compound 19 (FIG. 8, step i).
[0114] The protective groups of m62'OMeAp2'OMeG dinucleotide intermediate compound are removed (FIG. 8, step ii) as described in Example 4 to produce m62'OMeA- 2'OMeG dinucleotide compound 20. The 5'-hydroxy group of the adenosine group is phosphorylated according to the method of Lewdorowicz 2007 (FIG. 8, step iii). Phosphorus trichloride oxide in trimethyl phosphate is cooled to 4°C and m62'-OMeA-2'-OMeG is added and stirred at 4°C for 3 hours. Tetraethylammoniuum bromide (TEAB) is added to neutralize the mixture to produce the m62'OMeAp2'OMeG dinucleotide 5'-monophosphate (FIG. 8, compound 21).
Example 8:
[0115] Trinucleotide cap analog, m7G(5')ppp m62'OMeAp2'OMeG (compound 22, FIG. 9). The trinucleotide cap analog is produced by the method described in Example 5. A mixture of ammonium salt of pApG (compound 21 produced in Example 7), four equivalents of a sodium salt of m7GDP-IM (compound 3 produced in Example 1), and ZnCh in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield m7G(5')pppm62'OMeAp2'OMeG (compound 22).
Example 9
[0116] 2'-0,4'-C-methylene-linked bicyclic guanine nucleotide (compound 32, FIG. 10). The locked guanine nucleotide was synthesized according to the method shown in FIG. 10 starting with commercially available ((3aS,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3- d][l,3]dioxole-5,5-diyl)dimethanol (compound 23) using the method of Koshkin, 2001, J Org Chem, 66:8504-12 (hereby incorporated by reference). The diol compound 23 in anhydrous pyridine was cooled in an ice bath and methanesulfonyl chloride (MsCl) is added. The mixture is stirred for 1 hour at room temperature, diluted with ethyl ether, and washed with water. The organic layer was dried (Na2S04), concentrated under reduced pressure, co-evaporated with toluene, and dried in vacuo (FIG. 10, step i) to yield compound 24. A solution of this product in 80% trifluoroacetic acid was stirred at room temperature for one hour. The solvents were removed under pressure and the residue is dissolved in dichloromethane (DCM) and washed with saturated NaHCCb to yield compound 24.
[0117] Compound 24 was co-evaporated with anhydrous pyridine, dissolved in anhydrous pyridine, and treated with Ac20 overnight. The reaction mixture was quenched by addition of saturated NaHCCb and washed with ethyl acetate. The organic layers were combined, washed with brine, dried, and concentrated under pressure (FIG. 10, step ii) to produce a mixture of two isomers of compound 25.
[0118] N,O-i¾'s(trimethylsilyl)acetamide (BSA) was added to a mixture of compound 25 and butyrated guanine in anhydrous acetonitrile. After refluxing for one hour, trimethylsilyl triflate is added and refluxing was continued further for 4 hours to produce a guanine nucleotide compound 26 (FIG. 10, step iii). The solution was cooled to room temperature, diluted with DCM, and washed with saturated NaHCCb. The organic layer was dried, and concentrated under reduced pressure to obtain modified guanine nucleotide intermediate compound 26.
[0119] To a solution of the modified guanine nucleotide compound 26 in 1,4- dioxane/water (1 : 1, v:v) was added 2 M NaOH. After stirring 1 hour at room temperature, the reaction was diluted with saturated NaHCCb and extracted with DCM (FIG. 10, step iv) to produce the modified bicycle guanine nucleotide. The organic layers were dried and
concentrated to obtain the bicyclic product compound 27.
[0120] Compound 27 was reacted with sodium benzoate in anhydrous DMF and stirred for 5 hours at 100°C (FIG. 14, step v). The mixture containing the 5'O-protected compound 28 was cooled, filtered, and suspended in ethyl acetate, washed with water, and dried.
[0121] H20 and 2 M NaOH are added to a solution of compound 28 in 1,4-dioxane. The reaction mixture was refluxed for 24 hours, cooled to room temperature, and neutralized with acetic acid (FIG. 10, step vi) to produce compound 29 having a free 5ΌΗ. Saturated NaHC03 was added, and the mixture was washed with DCM. Organic layers were combined, dried (Na2S04), and concentrated under reduced pressure.
[0122] To a solution compound 29 in methanol was added 20% Pd(OH)2/C, and HC02H. After refluxing the mixture for 10 min, the catalyst was filtered off and washed with methanol (FIG. 14, step vii). The combined filtrates were concentrated to obtain compound 30 with free 3' and 5' OH groups. [0123] The 5' OH group of compound 30 was blocked as a DMTr ether according to the method of WO 99/14266 by preparing an anhydrous pyridine solution of the nucleotide, adding an excess of 4,4'-dimethoxytrityl chloride, stirring at room temperature for 2 hours, quenching the reaction with ice cold water, and extracting the product with DCM (FIG. 10, step viii). The combined organic phases were washed NaHC03-saturated water, brine, and dried Na2S04 to give compound 31.
[0124] The 3'-OH group of the nucleotide 31 was blocked by an acyl group according to the method of WO 2009/124238 (hereby incorporated by reference). The 3' hydroxy group compound 31 was acylated with alkoyl chloride, triethylamine in DCM, followed by removal of the 5'O-DMTr group with hexafluoroisopropanol or aqueous acid to produce the locked guanyl nucleotide, compound 32 (FIG. 10, step viii).
Example 10
[0125] Dinucleotide m62'OMeAp-locked-2'OMeG (compound 35, FIG 11) The dinucleotide was produced by combining locked guanyl nucleotide, compound 32 (Example 9) with benzoylated 3'-p-m62'-OMeA compound 18 (Example 6) by the method of Lewdorowicz 2007. Locked guanyl compound 32 was mixed with 1 equivalent of benzoylated 3'-p-m62'- OMeA compound 18 in anhydrous acetonitrile and the mixture was dried by evaporation. A solution of 2,4,6,-triisopropylbenzenesulfonyl chloride and N-methylimidazole in acetonitrile was added and reacted for 4 hours to produce the protected m62'-OMeAp-locked-2'-OMeG dinucleotide compound 33 (FIG. 11, step i).
[0126] The protective groups of dinucleotide compound 33 were removed (FIG. 11, step ii) as described in Example 4 to produce m62'OMeA-locked-2'-OMeG dinucleotide compound 34. The 5'-hydroxy group of the adenosine group was phosphorylated according to the method of Lewdorowicz 2007 (FIG. 11, step iii). Phosphorus trichloride oxide in trimethyl phosphate was cooled to 4°C and m62'OMeA-2'OMeG was added and stirred at 4°C for 3 hours. Tetraethylammoniuum bromide (TEAB) was added to neutralize the mixture to produce the m62'-OMeAp-locked-2'-OMeG dinucleotide 5'-monophosphate (FIG. 11, compound 35).
Example 11
[0127] Trinucleotide cap analog, m7G(5')pppm62'OMeAp-locked-2'-OMeG
(compound 36, FIG. 12). The trinucleotide cap analog is produced by the method described in Example 5. A mixture of ammonium salt of m62'-OMeAp-locked-2'-OMeG dinucleotide 5'- monophosphate (compound 35 produced in Example 10), four equivalents of a sodium salt of m7GDP-IM (compound 3 produced in Example 1), and ZnCh in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield m7G(5')pppm62'- OMeAp-locked-2'-OMeG (compound 36).
Example 12
[0128] (R)-3-hydroxy-2-((R)-l-(2-isobutyramido-6-oxo-l,6-dihydro-9H-purin-9- yl)-2-methoxyethoxy)propyl isobutyrate
(2'OMe-seco-3'-0-isobutyryl,N2-isobutyrylguanosine; FIG. 13, compound 43). The 5' OH group of N2-isobutyrylguanosine compound 37 was blocked by as a DMTr ether according to the method of WO 99/14266 by preparing a anhydrous pyridine solution of the nucleotide, adding an excess of 4,4'-dimethoxytrityl chloride, stirring at room temperature for 2 hours, quenching the reaction with ice cold water, and extracting the product (compound 38) with DCM (FIG. 13, step i). The combined organic phases were washed with NaHC03-saturated water, brine, and dried Na2S04.
[0129] Guanosine compound 38 was converted to an "unlocked" form of compound 39 by the method of Landkjaer, 2009, BiorgMed Chem, 17:5420-25 (hereby incorporated by reference). The DMTr guanosine compound 38 was dissolved in a stirred mixture of dioxane and water. To this mixture was added NaI04 dissolved in water, stirred for one hour, and further dioxane is added. The suspension was filtered and the filter cake was washed with dioxane. The filtrates were combined and sodium borohydride was added and the mixture stirred for 30 minutes (FIG. 17, step ii). The mixture was neutralized by addition of pyridine:acetic acid buffer. After evaporation, DCM is added and the mixture was washed with saturated aqueous NaHC03. The organic phase was separated and evaporated to dryness under reduced pressure, to yield 5'0-DMT-2',3'-secoguanine.
[0130] 2'-0-benzoyl-5'-0-DMT-2',3'-secoguanine compound 39 was prepared from 5'0-DMT-2',3'-secoguanine by the method of Landkjaer 2009. The nucleotide was co- evaporated with anhydrous toluene and dried for 12 hours in vacuo. The residue was dissolved at room temperature in anhydrous mixture of DCM with pyridine and cooled to -78°C. Benzoyl chloride was added over 15 minutes with stirring for 1 hour at -78°C. The mixture was warmed to room temperature, and ethanol was added and the mixture was washed with saturated aqueous NaHC03 and the separated aqueous phase was back-extracted with DCE. The organic phases were combined and evaporated to dryness to yield the 2'-0-benzoylated secoguanine compound 39 (FIG. 13, step ii).
[0131] The 3'-OH group of the the 2'-0-benzoylated secoguanine was protected by TBDMSC1 according to the method of Perlikova 2014, ChemBioChem, 15: 146-156 (hereby incorporated by reference) (FIG. 13, step iii) to yield compound 40.
[0132] The 2'-0-benzoyl group compound 40 was removed by the method of Nishino, 1985, Tetrahedron, 41 :5503-06 (hereby incorporated by reference) using a suspension of sodium methoxide in THF for 1 hour at room temperature (FIG. 13, step iv). The reaction was quenched by neutralization to yield the free 2'-OH group of compound 41.
[0133] The 2'-OH group of compound 41 was methylated by reaction with NaH and methyl iodide in THF at 0°C (step v) to yield compound 42. The silyl group was removed from the 3'-OH group with nBu4 F by the method of Perlikova 2014 and the 3'-OH group was butyrlated (step v) to produce the secoguanine compound 43 after removal of the DMTr protecting group with acid (CF3CO2H, step vi).
Example 13
[0134] ((2R,3S,4S,5R)-3-((((S)-2-((R)-l-(2-amino-6-oxo-l,6-dihydro-9H-purin-9- yl)-2-methoxyethoxy)-3-hydroxypropoxy)(hydroxy)phosphoryl)oxy)-4-methoxy-5-(6- (methylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl hydrogen phosphate
(p-2'-OMe-m6Ap-seco-2'-OMeG, FIG. 14, compound 46). Protected 2'0MeAp2'0MeG dinucleotide, compound 44 (FIG. 14) was produced by combining 3'-p-2'-OMeA compound 18 (Example 6) with protected 2'-OMe secoguanosine compound 43 (Example 12) by the method of Lewdorowicz 2007. First, 3'-p-2'-OMeA compound 18 was mixed with an equivalent of 2'OMe guanosine compound 43 in anhydrous acetonitrile and the mixture was dried by evaporation. A solution of 2,4,6,-triisopropylbenzenesulfonyl chloride and N-methylimidazole in acetonitrile was added and the mixture was reacted for 4 hours to produce compound 44 (FIG. 14, step i).
[0135] The protective groups of compound 44 were removed (step ii, using reactions described in Example 4, FIG. 5, step i), to produce a 2'-OMeA-2'-OMeG dinucleotide compound 45. The 5'-hydroxy group of the adenosine group was phosphorylated according to the method of Lewdorowicz 2007 (FIG. 14, step iii). Phosphorus trichloride oxide in trimethyl phosphate was cooled to 4°C and the 5'-0-guanine-adenine dinucleotide-3'-0 compound 45 was added and stirred at 4°C for 3 hours. Tetraethylammoniuum bromide (TEAB) was added to neutralize the mixture to produce 2'-OMe-m6Ap-seco-2'-OMeG 5 '-monophosphate, compound 46.
Example 14
[0136] Trinucleotide cap analog, m7G(5')pppm62'-OMeAp-seco-2'-OMeG
(compound 54, FIG. 19). The trinucleotide cap analog is produced by the method described in Example 8. A mixture of ammonium salt of 2'-OMe-m6Ap-seco-2'-OMeG 5'-monophosphate, compound 53 (produced in Example 16), four equivalents of a sodium salt of m7GDP-EVI (compound 1 produced in Example 1), and ZnC12 in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield m7G(5')pppm62'OMeAp- seco-2'OMeG (compound 54).
Example 15
[0137] (2R,3^,4^,5R)-2-(hydroxymethyl)-5-(2-isobutyramido-6-oxo-l,6-dihydro-9H- purin-9-yl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate (2'-0-isobutyryl-3'0-isobutyryl,N2- isobutyrylguanosine, FIG. 16, compound 50) is synthesized from commercially available guanosine (compound 48) by the method of Wolf, 2008, Org Biomol Chem, 6:899-907 (hereby incorporated by reference). First, guanosine is isobutyrated at the N2 position and crystallized from water to give N2-isobutyrylguanosine, and the 5'-hydroxy group is protected with a DMTr group (FIG. 16, step i) according to the method of WO 99/14266 to yield compound 49. Second, 2'- and 3' hydroxy groups are subject to isobutyrylation, and the DMTr group is removed by treatment with 5% trichloroacteic acid to produce 2'-0-isobutyryl,3'-0-isobutyryl,N2- isobutyrylguanosine, compound 50 (FIG. 16, step ii).
Example 16
[0138] ((2R,3^,4^,5R)-3-(((((2R,3R,4S,5R)-5-(2-amino-6-oxo-l,6-dihydro-9H-purin-9- yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)oxidophosphoryl)oxy)-5-(6-amino-9H-purin-9- yl)-4-methoxytetrahydrofuran-2-yl)methyl hydrogen phosphate (p-2'-OMe-ApG, FIG. 18, compound 53). To synthesize p-2'-OMe-ApG, compound 6 (5'0-DMT-2'0-Me-N6benzoyl- AMP-PhCl, Example 2) is combined with with isobutyrated guanosine compound 50 (Example 15) by the method of Lewdorowicz 2007. Compound 6 is mixed with an equivalent of isobutyrated guanosine compound 50 in anhydrous acetonitrile. The mixture is dried by evaporation. A solution of 2,4,6,-triisopropylbenzenesulfonyl chloride and N-methylimidazole in acetonitrile is added and the mixture is reacted for 4 hours to produce the protected 2'-OMe- ApG dinucleotide compound 51 (FIG. 17, step i).
[0139] The protective groups of 2'-OMeApG dinucleotide compound 51 are removed using known reactions, e.g., by a method selected from Lewdorowicz 2007; Huss, 1988, J Org Chem, 53 :499-506; Zhou, 1986, Tetrahedron, 42:4149-56; Reese, 1986, Tetrahedron Letters, 27:2291-94; Abramova, 2008, BiorgMed Chem, 16:9127-32; Abramova, 2013, Beilstein J Org Chem, 9:2898-909; Hashmi, 1994, Nucleotides & Nucleotides, 13 : 1059-67; Hsu, 1985, Nucleotides & Nucleotides, 4:377-89; Puech, 1988, JMed Chem, 31 : 1897-907 (hereby incorporated by reference) (FIG. 18, step i) to produce 2'-OMe-ApG dinucleotide (compound 52). The 5'-hydroxy group of compound 52 is phosphorylated according to the method of Lewdorowicz 2007 (step ii). Phosphorus trichloride oxide in trimethyl phosphate is cooled to 4°C and the 5'-0-guanine-adenine dinucleotide-3'-0 intermediate is added and stirred at 4°C for 3 hours. Tetraethylammoniuum bromide (TEAB) is added to neutralize the mixture to produce p-2'-OMe-ApG dinucleotide (FIG. 18, compound 53).
Example 17
[0140] Trinucleotide cap analog, m7G(5')ppp-2'OMeApG (compound 54 of FIG. 19). The trinucleotide cap analog is produced by the method of Lewdorowicz 2007. A mixture of ammonium salt of pApG (compound 53 produced in Example 18), four equivalents of a sodium salt of m7GDP-IM (compound 3 produced in Example 1), and ZnCh in DMF is stirred for 2 days at room temperature. The reaction is quenched by addition of water to yield m7G(5')ppp-2'OMeApG (compound 54).
Example 18
[0141] In Vitro transcription reaction: For ARCA and ARC CAPl mRNAs, in vitro transcription was performed using the standard protocol (see Table, below). All of components were mixed, and T7 RNA polymerase (E2040 from NEB) was added in the reaction mixture. The transcription reaction was incubated for 2 hrs at 37C. After 2 hrs of reaction time, DNASEI (NEB) and buffer were added to the transcription reaction, and incubated for 15 mins at 37C. The crude of reaction mix was purified using RNA purification kit (Macherey-Nagel). [0142]
Figure imgf000033_0001
* ARCA, 3'-OMe-m7G(5')p3G (Trilink)
** ARC CAP 1, m7G(5')p3AmpG
[0143] For Vaccinia mRNA, in vitro transcription was performed using the standard protocol without ARCA or ARC CAPl . All of components were mixed, and T7 RNA
polymerase (E2040 from NEB) was added in the reaction mixture. The transcription reaction was incubated for 2 hrs at 37C. After 2 hrs of reaction time, DNASEI (NEB) and buffer were added to the transcription reaction, and incubated for 15 mins at 37C. The crude of reaction mix was purified using RNA purification kit (Macherey-Nagel). The RNA was denatured at 65 °C for 5 min and then snap chilled to relieve any secondary conformations. For the total 1 mL capping reaction, 1 mg denatured RNA in 700 [iL of nuclease-free water was used along with 100 μΐ^ 1 (10x) capping buffer, 50 uL (10 mM) GTP, 50 uL (4 mM) SAM, 50 uL of (10 units^)
Vaccinia capping enzyme, and 50 μΐ^ of mRNAcap2'-0-methyltransferase at (50 units^L) were combined and incubated at 37 °C for 1 h. The mixture capped mRNA was purified using RNA purification kit (Macherey-Nagel). [0144] m7G(5')p3-RNA were delivered 0.3 mg/kg i.v. into 12-16 weeks old male mice. Blood samples were collected at 6 hours post dose, and plasma was isolated. Protein expression was performed using ELISA (e.bioscience). Results are shown in FIG. 16.
[0145] The results show that the efficiency of transcription using trinucleotide analog ARC CAPl is substantially improved compared to dinucleotide ARCA. This is because the amount of protein expression for ARC CAPl is greater than ARCA, and because vaccinia- mediated capping produces m7G(5')p3-RNA that results in comparable protein expression compared to ARC CAPl . ARC CAPl-RNA is just as efficient translated as enzymatically capped RNA.
[0146] Although the present disclosure is described with respect to certain
embodiments and examples, various modifications may be made without departing from the spirit and scope of the invention.

Claims

What is claimed is as follows:
1. A compound of formula m G(5')p3(5')N1pN2,
wherein m7G is a ribonucleotide consisting of N7-methylguanine and a ribose; wherein (5')ρ3(5') is a 5' to 5' triphosphate linkage, and
wherein Ni and N2 are ribonucleotides, wherein one or both of Ni and N2 consist of a base selected from N6-methyladenine, N^methyladenine, pseudouruacil, N1- methylpseudouracil, 5-iodouracil, 4-thiouracil, 2-thiouracil, 5-methyluracil, pseudoisocytosine, 5-methoxycytosine, 2-thiocytosine, 5-hydroxycytosine, N4- methylcytosine, 5-hydroxymethylcytosine, hypoxanthine, N^methylguanine, O6- methylguanine, 1-methyl-guanosine, N2-methyl-guanosine (m2G), N2,N2- dimethyl-guanosine (m2,2G), 2-methyl-2'-0- methyl-guanosine (m2Gm), N2,N2- dimethyl-2'-0-methyl-guanosine (m2,2Gm), 1 -methyl-2'-0-methyl-guanosine, N2,N7-dimethyl-2'-0-methyl-guanosine (m2,7Gm), or isoguanineadenine; and a ribose, a bicyclic (LNA) ribose, a seco (UNA) ribose, or a modified ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent; and
wherein the m7G ribonucleotide is linked at its 5'-OH to the triphosphate bridge,
wherein the triphosphate bridge is linked to a 5'-OH of the Ni ribonucleotide, wherein Ni nucleotide is linked via its 3'-OH to a phosphate, p, wherein the phosphate is linked to a 5'-OH of the N2 ribonucleotide;
or a salt or solvated form thereof.
2. The compound of claim 1, wherein Ni is a ribonucleotide consisting of adenine, uridine, guanine, or cytidine.
3. The compound of claim 2, wherein Ni consists of adenine.
4. The compound according to any one of claims 1-3, wherein N2 consists of N^methylguanine, 06-methylguanine, 1-methyl-guanosine, m2G, m2,2G, m2Gm, m2,2Gm, l-methyl-2'-0-methyl- guanosine, m2,7Gm, or isoguanineadenine.
5. The compound of claim 4, wherein N2 consists of N^methylguanine, 06-methylguanine, or i soguanineadenine
6. The compound according to any one of claims 1-5, wherein Ni consists of a LNA, a UNA, or a ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent.
7. The compound of claim 1, wherein N2 is a ribonucleotide consisting of adenine, uridine, guanine, or cytidine.
8. The compound of claim 7, wherein N2 is a ribonucleotide consisting of guanine.
9. The compound according to any one of claims 1 and 7-8, wherein N2 is a ribonucleotide consisting of a LNA, a UNA, or a ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent.
10. The compound of claim 1, wherein the trinucleotide cap analog is m7G(5')p3AmpGm, wherein Am is 2'OMe-adenine and Gm is 2'OMe-guanine.
11. The compound of claim 1, wherein the compound is m7G(5')p3m6AmpGm, wherein 6mAm is 2'0Me-N6methyladenine and Gm is 2'OMe-guanine.
12. The compound of claim 1, wherein the compound is m7G(5')p3m6AmpGLNA, wherein 6mAm is 2'0Me-N6methyladenine and GLNA is guanine bicyclic (LNA)-ribose.
13. The compound of claim 1, wherein the compound is m7G(5')p3m6AmpGuNA, wherein 6mAm is 2'0Me-N6methyladenine and GUNA is guanine seco(UNA)ribose.
14. The compound of claim 1, wherein at least one ribose of the m7G, Ni, or N2 ribonucleotide is a LNA.
15. The compound of claim 1, wherein at least one ribose of m7G, Ni, or N2 ribonucleotide is a UNA.
16. The compound of claim 1, wherein at least one ribose of m G, Ni, or N2 ribonucleotide is substituted by a 2'-Cl-C6-alkoxy.
17. The compound according to any one of claims 1-9, wherein at least one ribose of Ni or N2 ribonucleotide is substituted by a 2'-OMe.
18. The compound according to any one of claims 1-9 and 17, wherein the triphosphate bridge consisting of 1, 2, or 3 phosphorothioate groups.
19. The compound according to any one of claims 1-18, wherein the compound increases the efficiency of m7G(5')p3-RNA produced by in vitro transcription compared to 3'-OMe-
Figure imgf000037_0001
20. The compound of claim 19, wherein in vitro transcription is mediated by T7 RNA polymerase or T6 RNA polymerase.
21. A compound of formula m7G(5')p3-NipN2,
wherein m7G is a ribonucleotide consisting of N7-methylguanine and a ribose, wherein (5')p3 is a 5' to 5' triphosphate linkage;
wherein Ni and N2 are ribonucleotides, wherein one or both of Ni and N2 ribonucleotides consist of a base selected from adenine, uracil, cytosine, or guanine; and a bicyclic (LNA) ribose, a seco (UNA) ribose, or a modified ribose wherein one or both of the ribose 2' or 3' carbons has a fluoro or a C1-C6 alkoxy substituent; and
wherein the m7G ribonucleotide is linked at its 5'-OH to the triphosphate bridge, wherein the triphosphate bridge is linked to a 5'-OH of the Ni ribonucleotide, wherein Ni nucleotide is linked via its 3'-OH to a phosphate, p, wherein the phosphate is linked to a 5'-OH of the N2 ribonucleotide;
or a salt or solvated form thereof.
PCT/US2017/057481 2016-10-19 2017-10-19 Trinucleotide mrna cap analogs WO2018075827A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP17804982.1A EP3529255A1 (en) 2016-10-19 2017-10-19 Trinucleotide mrna cap analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410325P 2016-10-19 2016-10-19
US62/410,325 2016-10-19

Publications (1)

Publication Number Publication Date
WO2018075827A1 true WO2018075827A1 (en) 2018-04-26

Family

ID=60480365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/057481 WO2018075827A1 (en) 2016-10-19 2017-10-19 Trinucleotide mrna cap analogs

Country Status (3)

Country Link
US (2) US10487105B2 (en)
EP (1) EP3529255A1 (en)
WO (1) WO2018075827A1 (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424524A2 (en) 2017-07-04 2019-01-09 CureVac AG Cancer rna-vaccine
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
WO2020002598A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
WO2020127959A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
WO2021001739A1 (en) * 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
WO2021123332A1 (en) 2019-12-20 2021-06-24 Curevac Ag Lipid nanoparticles for delivery of nucleic acids
WO2021156267A1 (en) 2020-02-04 2021-08-12 Curevac Ag Coronavirus vaccine
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
KR102366490B1 (en) * 2020-10-20 2022-02-23 에스티팜 주식회사 Oligonucleotides for synthesizing 5'-capped RNA
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2022049093A1 (en) 2020-09-01 2022-03-10 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
WO2022112498A1 (en) 2020-11-27 2022-06-02 CureVac RNA Printer GmbH A device for preparing a dna product by means of capillary polymerase chain reaction
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US20220273820A1 (en) * 2020-04-22 2022-09-01 BioNTech SE Rna constructs and uses thereof
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
US11471525B2 (en) 2020-02-04 2022-10-18 Curevac Ag Coronavirus vaccine
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
WO2023006999A2 (en) 2021-07-30 2023-02-02 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
WO2023007019A1 (en) 2021-07-30 2023-02-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023073190A1 (en) * 2021-10-28 2023-05-04 BioNTech SE Rna constructs and uses thereof
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023147352A1 (en) * 2022-01-27 2023-08-03 Trilink Biotechnologies, Llc Trinucleotide cap analogs and methods of use thereof
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
WO2023159930A1 (en) * 2022-02-28 2023-08-31 广州市恒诺康医药科技有限公司 Compound for rna capping and application of compound
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11872280B2 (en) 2020-12-22 2024-01-16 CureVac SE RNA vaccine against SARS-CoV-2 variants
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017375A1 (en) * 2022-07-22 2024-01-25 广州市恒诺康医药科技有限公司 Cyclic substituted compound for rna capping and use thereof
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
US11964012B2 (en) 2020-02-04 2024-04-23 CureVac SE Coronavirus vaccine

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113584020A (en) 2015-09-21 2021-11-02 垂林克生物技术公司 Compositions and methods for synthesizing 5' -capped RNA
JP7408098B2 (en) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド RNA polymerase variants
CN110818748A (en) * 2018-08-07 2020-02-21 广州市锐博生物科技有限公司 Synthesis method of nucleoside compound and intermediate thereof
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
CA3114892A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
HUE064076T2 (en) 2018-12-06 2024-02-28 Arcturus Therapeutics Inc Compositions and methods for treating ornithine transcarbamylase deficiency
MA55037A (en) 2019-02-20 2021-12-29 Modernatx Inc RNA POLYMERASE VARIANTS FOR CO-TRANSCRIPTIONAL STYLING
GB2597423A (en) * 2019-05-10 2022-01-26 New England Biolabs Inc Chemical capping for template switching
EP4017994A1 (en) 2019-08-22 2022-06-29 New England Biolabs, Inc. Cleavage of single stranded dna having a modified nucleotide
WO2021041260A1 (en) 2019-08-23 2021-03-04 New England Biolabs, Inc. Enzymatic rna capping method
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
AU2021236068A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
CN113122597A (en) * 2020-08-20 2021-07-16 深圳市瑞吉生物科技有限公司 Cap analog 5' with Cap2 structure and preparation method and application thereof
AU2021412833A1 (en) 2020-12-28 2023-07-06 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
CN113603739A (en) * 2021-08-27 2021-11-05 上海兆维科技发展有限公司 Capped analog and application thereof
WO2023167880A2 (en) * 2022-03-01 2023-09-07 Verve Therapeutics, Inc. Compositions and methods for capping rnas
US20230287376A1 (en) 2022-03-11 2023-09-14 New England Biolabs, Inc. Immobilized enzyme compositions and methods
CN114685588B (en) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 Initial capping oligonucleotide primer containing open-loop nucleoside structure
CN114853836A (en) * 2022-06-24 2022-08-05 江苏申基生物科技有限公司 Initial capped oligonucleotide primer containing GNA structure and preparation method and application thereof
CN115057903B (en) * 2022-06-22 2024-03-29 江苏申基生物科技有限公司 Initial capping oligonucleotide primer containing morpholine ring structure and preparation method and application thereof
CN116768950B (en) * 2023-08-16 2023-11-03 江苏申基生物科技有限公司 Initial capping oligonucleotide primer and application thereof
CN117343111B (en) * 2023-12-04 2024-02-06 康羽生命科学技术(苏州)有限公司 Preparation method of nucleoside modifier N2-isobutyryl-2' -methoxy guanosine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014266A1 (en) 1997-09-17 1999-03-25 Japan Polychem Corporation Resin material for foam molding, foamed sheet obtained therefrom, and process for producing the same
WO1999014226A2 (en) 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
WO2009124238A1 (en) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
WO2013130161A1 (en) * 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
US9051570B2 (en) 2007-05-22 2015-06-09 Arcturus Therapeutics, Inc. UNA oligomers for therapeutics
WO2017053297A1 (en) * 2015-09-21 2017-03-30 Trilink Biotechnologies, Inc. Compositions and methods for synthesizing 5'-capped rnas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066793A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
ES2914225T3 (en) 2015-10-16 2022-06-08 Modernatx Inc Modified phosphate bond mRNA cap analogs

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
WO1999014226A2 (en) 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO1999014266A1 (en) 1997-09-17 1999-03-25 Japan Polychem Corporation Resin material for foam molding, foamed sheet obtained therefrom, and process for producing the same
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US9051570B2 (en) 2007-05-22 2015-06-09 Arcturus Therapeutics, Inc. UNA oligomers for therapeutics
US9297009B2 (en) 2007-05-22 2016-03-29 Arcturus Therapeutics, Inc. UNA oligomers targeting micro-RNA for therapeutics
WO2009124238A1 (en) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
WO2013130161A1 (en) * 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
WO2017053297A1 (en) * 2015-09-21 2017-03-30 Trilink Biotechnologies, Inc. Compositions and methods for synthesizing 5'-capped rnas

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
ABRAMOVA, BEILSTEIN J ORG CHEM, vol. 9, 2013, pages 2898 - 909
ABRAMOVA, BIORG MED CHEM, vol. 16, 2008, pages 9127 - 32
ABRAMOVA, BIORGMED CHEM, vol. 16, 2008, pages 9127 - 32
CANAANI D ET AL: "SEQUENCE HETEROGENEITY AT THE 5' TERMINI OF LATE SIMIAN VIRUS 40 19S AND 16S MRNAS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, NEW YORK, NY, US, vol. 76, no. 7, 1 July 1979 (1979-07-01), pages 3078 - 3082, XP000607076 *
CHONG H KIM ET AL: "Spatial configuration of the bizarre 5' terminus of mammalian mRNA", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1 March 1978 (1978-03-01), pages 1571 - 1590, XP055443699, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/ja00473a040> DOI: 10.1021/ja00473a040 *
FRANÇOIS BÉLANGER ET AL: "Characterization of hMTr1, a Human Cap1 2'- O -Ribose Methyltransferase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 43, 22 October 2010 (2010-10-22), pages 33037 - 33044, XP055443707, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.155283 *
HASHMI, NUCLEOTIDES & NUCLEOTIDES, vol. 13, 1994, pages 1059 - 67
HEISER, J CLIN INVEST, vol. 109, 2002, pages 409 - 17
HSU, NUCLEOTIDES & NUCLEOTIDES, vol. 4, 1985, pages 377 - 89
HUSS, J ORG CHEM, vol. 53, 1988, pages 499 - 506
HYDE, J MED CHEM, vol. 46, 2003, pages 1878 - 85
ISHIKAWA, NUCLEIC ACID SYMP. SER., vol. 53, 2009, pages 129 - 30
KORE, NUCLEOTIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, vol. 25, 2006, pages 307 - 14
KORE, NUCLEOTIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, vol. 25, 2006, pages 337 - 40
KOSHKIN, J ORG CHEM, vol. 66, 2001, pages 8504 - 12
KOSKIN, J ORG CHEM, vol. 66, 2001, pages 8504 - 12
LANDKJAER, BIORGMED CHEM, vol. 17, 2009, pages 5420 - 25
LEWDOROWICZ, NUCLEOTIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, vol. 26, 2007, pages 1339 - 48
M. ISHIKAWA ET AL: "Preparation of eukaryotic mRNA having differently methylated adenosine at the 5'-terminus and the effect of the methyl group in translation", NUCLEIC ACIDS SYMPOSIUM SERIES, vol. 53, no. 1, 1 September 2009 (2009-09-01), GB, pages 129 - 130, XP055331388, ISSN: 0261-3166, DOI: 10.1093/nass/nrp065 *
MORSE, INT J GASTROINTEST CANCER, vol. 32, 2002, pages 1 - 6
MULLER, J MED CHEM, vol. 58, 2015, pages 6248 - 6263
NISHINO, TETRAHEDRON, vol. 41, 1985, pages 5503 - 06
PERLIKOVA, CHEMBIOCHEM, vol. 15, 2014, pages 146 - 156
PIECYK, TETRAHEDRON LETTERS, vol. 53, 2012, pages 4843 - 47
PUECH, J MED CHEM, vol. 31, 1988, pages 1897 - 907
REESE, TETRAHEDRON LETTERS, vol. 27, 1986, pages 2291 - 94
SOMMER ET AL: "Prediction of the electrophoretic mobilities of nucleotides on neutral paper", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 98, no. 1, 15 September 1979 (1979-09-15), pages 8 - 12, XP024829919, ISSN: 0003-2697, [retrieved on 19790915], DOI: 10.1016/0003-2697(79)90698-5 *
WOLF, ORGBIOMOL CHEM, vol. 6, 2008, pages 899 - 907
Y. YOFFE ET AL: "Binding Specificities and Potential Roles of Isoforms of Eukaryotic Initiation Factor 4E in Leishmania", EUKARYOTIC CELL, vol. 5, no. 12, 1 December 2006 (2006-12-01), US, pages 1969 - 1979, XP055331392, ISSN: 1535-9778, DOI: 10.1128/EC.00230-06 *
ZHOU, TETRAHEDRON, vol. 42, 1986, pages 4149 - 56
ZHU, SYNTHETIC COMMUNICATIONS, vol. 33, 2003, pages 1233 - 43

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2019008001A1 (en) 2017-07-04 2019-01-10 Curevac Ag Novel nucleic acid molecules
EP3424524A2 (en) 2017-07-04 2019-01-09 CureVac AG Cancer rna-vaccine
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
WO2020002598A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
EP4273266A2 (en) 2018-06-28 2023-11-08 CureVac RNA Printer GmbH Bioreactor for rna in vitro transcription
WO2020127959A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
WO2021001739A1 (en) * 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
WO2021123332A1 (en) 2019-12-20 2021-06-24 Curevac Ag Lipid nanoparticles for delivery of nucleic acids
DE202021004123U1 (en) 2020-02-04 2022-10-26 Curevac Ag Coronavirus Vaccine
US11964011B2 (en) 2020-02-04 2024-04-23 CureVac SE Coronavirus vaccine
DE112021000012T5 (en) 2020-02-04 2021-11-18 Curevac Ag Coronavirus vaccine
WO2021156267A1 (en) 2020-02-04 2021-08-12 Curevac Ag Coronavirus vaccine
US11964012B2 (en) 2020-02-04 2024-04-23 CureVac SE Coronavirus vaccine
EP4147717A1 (en) 2020-02-04 2023-03-15 CureVac SE Coronavirus vaccine
US11596686B2 (en) 2020-02-04 2023-03-07 CureVac SE Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
DE202021004130U1 (en) 2020-02-04 2022-10-26 Curevac Ag Coronavirus Vaccine
DE202021003575U1 (en) 2020-02-04 2022-01-17 Curevac Ag Coronavirus Vaccine
US11471525B2 (en) 2020-02-04 2022-10-18 Curevac Ag Coronavirus vaccine
US20220273820A1 (en) * 2020-04-22 2022-09-01 BioNTech SE Rna constructs and uses thereof
US11951185B2 (en) 2020-04-22 2024-04-09 BioNTech SE RNA constructs and uses thereof
US11779659B2 (en) 2020-04-22 2023-10-10 BioNTech SE RNA constructs and uses thereof
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2022049093A1 (en) 2020-09-01 2022-03-10 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
KR102366490B1 (en) * 2020-10-20 2022-02-23 에스티팜 주식회사 Oligonucleotides for synthesizing 5'-capped RNA
WO2022086140A1 (en) 2020-10-20 2022-04-28 에스티팜 주식회사 Oligonucleotide for 5'-capped rna synthesis
WO2022112498A1 (en) 2020-11-27 2022-06-02 CureVac RNA Printer GmbH A device for preparing a dna product by means of capillary polymerase chain reaction
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US11872280B2 (en) 2020-12-22 2024-01-16 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
WO2023007019A1 (en) 2021-07-30 2023-02-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
WO2023006999A2 (en) 2021-07-30 2023-02-02 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023073190A1 (en) * 2021-10-28 2023-05-04 BioNTech SE Rna constructs and uses thereof
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023147352A1 (en) * 2022-01-27 2023-08-03 Trilink Biotechnologies, Llc Trinucleotide cap analogs and methods of use thereof
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023159930A1 (en) * 2022-02-28 2023-08-31 广州市恒诺康医药科技有限公司 Compound for rna capping and application of compound
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017375A1 (en) * 2022-07-22 2024-01-25 广州市恒诺康医药科技有限公司 Cyclic substituted compound for rna capping and use thereof
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines

Also Published As

Publication number Publication date
EP3529255A1 (en) 2019-08-28
US20200040026A1 (en) 2020-02-06
US10968248B2 (en) 2021-04-06
US10487105B2 (en) 2019-11-26
US20180105551A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
US10968248B2 (en) Trinucleotide mRNA cap analogs
US8309707B2 (en) RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end
CA2696497C (en) Tetrahydropyran nucleic acid analogs
JP4731324B2 (en) N-O bond cross-linked novel artificial nucleic acid
IL185569A (en) Cyclic nucleoside analogues
EA034605B1 (en) Novel rig-i ligands and methods for producing them
JP2021522862A (en) Oligonucleotide conjugate containing 7&#39;-5&#39;-alpha-anomeric bicyclic sugar nucleoside
TW201718618A (en) Cross-linked nucleic acid GuNA, preparation method of same, and intermediate for same
US20220089632A1 (en) Novel bicyclic nucleosides and oligomers prepared therefrom
US20240092819A1 (en) Novel ligands for asialoglycoprotein receptor
JP2017512774A (en) Synthesis of bicyclic nucleosides.
CA3198727A1 (en) Oligonucleotide for 5&#39;-capped rna synthesis
EP3643706B1 (en) Modified nucleic acid monomers and oligonucleic acid analogues, with high biological stability and target gene silencing activity, for use in therapy and diagnosis of cancer and viral diseases
WO2018156056A1 (en) Modified oligonucleotides activating rnase h
CA3190097A1 (en) Modified sirna with reduced off-target activity
AU3080899A (en) Novel nucleoside analogs and uses in treating disease
CN116003496A (en) Modified mRNA5&#39; -cap analogues
WO2014034934A1 (en) Oligonucleotide
US8618279B2 (en) Synthesis of 2′,3′— and 3′,5′—cyclic phosphate mono-and oligonucleotides
Kisakürek Perspectives in nucleoside and nucleic acid chemistry
CN101410406B (en) 6-modified bicyclic nucleic acid analogs
KR20230141482A (en) An mRNA cap analog and use thereof
KR20230083197A (en) Oligonucleotides for synthesizing 5&#39;-capped RNA
EP4047005A1 (en) Method for producing bicyclic phosphoramidite
WO2004048376A1 (en) Bicyclic naphthylidine nucleosides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17804982

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017804982

Country of ref document: EP

Effective date: 20190520